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ABSTRACT 
A CLINICAL AND SEROEPIDEMIOLOGICAL 
CASE-CONTROL STUDY OF 
TROPICAL SPASTIC PARAPARESIS AND MULTIPLE SCLEROSIS 
IN BARBADOS 
Cargill H. Alleyne, Jr 
(Sponsored by George Nicholson, faculty of Medical Sciences, 
Cave Hill campus, University of the West Indies and Francis L. 
Black, laboratory of Epidemiology and Public Health, Yale 
University School of Medicine) 
1991 
Tropical spastic paraparesis (TSP) and multiple sclerosis 
(MS) are both chronic neurological disorders which affect 
thousands of persons worldwide. Recently, studies have shown 
an association between the human T-lymphotropic virus type I 
(HTLV-I) and clusters of patients with TSP in several 
countries worldwide. More controversial has been the 
proposition that HTLV-I may be an etiological factor in MS. 
This age and sex matched case-control study examines the 
relationship between both TSP and MS and antibodies to HTLV-I 
in Barbados. It also examines the clinical, demographic and 
social characteristics of patients with TSP and MS compared 
with controls in an attempt to identify risk factors for these 

diseases as seen in Barbados. 
Four cases of TSP and 14 cases of MS were identified. 
Three relatives of MS cases agreed to participate. Serum 
HTLV-I antibodies were determined using an enzyme-linked 
immunosorbent assay (ELISA) and confirmed by Western blot 
analysis. All sera were tested for antibody to Treponema 
pallidum and for antibody to Borrelia burgdorferi, the agent 
of Lyme disease. Test results indicated that 2 TSP patients 
(50%) and none of the MS patients or relatives were 
seropositive for HTLV-I. None of the controls of either group 
was seropositive for HTLV-I. None of the sera from the cases 
was VDRL reactive while antibody to Treponema pallidum was 
confirmed by Treponema pallidum hemagglutinin assay (TPHA) in 
1 MS control. IgM and IgG antibodies to the agent of Lyme 
disease were also tested by ELISA. No increase in titers was 
noted in either cases or controls. In general, computer 
analysis of the data revealed no significant difference in the 
responses and characteristics of the cases as compared with 
the controls. 
These data suggest an association of HTLV-I with TSP but 
do not suggest a role of HTLV-I in the etiology of MS as 
diagnosed in Barbados. There is no support for an etiological 
role of Treponema pallidum or Borrelia burgdorferi in either 
MS or TSP. The absence of HTLV-I positivity in MS patients 
suggest that TSP cases are not being misdiagnosed as MS in 
Barbados. 
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INTRODUCTION 
Historical aspects of TSP 
Case reports of chronic neurological disorders of unknown 
etiology from a tropical area were first published in 1888 by 
1 , ... 
Strachan when he described a group of Jamaican patients with 
an ataxic peripheral neuritis, paresthesiae and defects in 
. . . 2 
vision. A similar syndrome was described by Scott in 1918 
when an epidemic began in Jamaican canecutters. It was 
reported to be preceded by conjunctivitis and stomatitis and 
characterized by numbness, tingling and burning of the feet, 
constipation and gait ataxia. Scott ascribed the neurological 
symptoms to a toxic factor, most likely sugarcane since this 
cyanogenic crop36 comprised the bulk of the patients' diet 
during the sugarcane season. Another possibility is that 
these cases represented a post-infectious acute sensory 
neuronopathy syndrome7 associated with an epidemic viral 
outbreak of acute hemorrhagic conjunctivitis. This 'Strachan- 
Scott syndrome' became known as tropical ataxic neuropathy 
(TAN). 
TAN was soon reported throughout the tropics and has been 
linked to a variety of nutritional disorders including vitamin 
A, riboflavin, niacin, folate, B12 and iron deficiencies.812 
TAN has also been noted in World War II prisoners of war 
(Canadians held by the Japanese, prisoners held in Singapore, 
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and Dutch, British and Indian prisoners held in Malaya, 
Thailand and Singapore)1315 and in conjunction with post- 
infective tropical malabsorption. In addition, cassava 
(Manihot esculenta) neurotoxicity has been implicated in 
TAN.5'19'20 
, . . . 21 
In 1956 Cruickshank described a neuropathic disorder 
which seemed clinically different from the syndrome described 
by Strachan and Scott. By 1964 it had become clear that this 
second “Jamaican neuropathy' had become predominant in 
Jamaica. Whereas TAN is characterized by a sensory ataxia due 
to symmetrical dorsal column lesions, this syndrome, also 
known as tropical spastic paraparesis (TSP), is characterized 
by bilateral and symmetrical involvement of the pyramidal 
tract especially at the lumbar level. This usually leads to 
a gradual onset of spasticity and hyperreflexia of the legs 
with a positive Babinski reflex. Also common are lumbar back 
pain, leg weakness, dysesthesiae of the feet, bladder 
dysfunction, severe constipation and impotence in males. In 
some cases there may also be slight involvement of the dorsal 
columns. Mental and cranial nerve functioning are usually 
normal except in Jamaica where deafness and retrobulbar 
neuropathy have occurred. 
Epidemic TSP has been linked to excessive cassava 
• • . . . 5 20 22 23 
consumption during drought m Nigeria and Mozambique, ' ' ' to 
. 24 
malabsorption, and to lathyrism (caused by excessive 
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consumption of peas of the Lathyrus 
25 26 
family in India and parts of Africa). ' An infectious agent 
. . . . 27 
may also be involved m some epidemics of TSP. 
Demographics of TSP 
The endemic form of TSP has now been recognized in 
Martinique, Trinidad, Colombia, the Seychelles, 
37 38 
Peru, South India and other countries, as well as in 
. 39 
Jamaica. The highest prevalence ratio of TSP to date (127.7 
cases per 100,000 population) has been reported in a 
, o . 34 
geographic isolate in the Seychelles by Kelly and De Mol. 
The sex distribution seems roughly balanced with a slight 
. . 33 34 40 
male preponderance in large studies ' ' but a marked female 
. . 29 35 , 
preponderance in smaller studies. ' One explanation given by 
Roman for this female preponderance is that it probably 
reflects 
a bias in the ascertainment of cases, since 
women may tend to seek medical attention more often 
than men, or since they may be more seriously 
affected. Both sexes would therefore seem to be 
equally exposed to the potential cause of TS^P, 
although women appear to be affected more often. 
The mean age of onset is 42 years and symptoms begin 
after 30 years of age in 76-82% of patients, but in a smaller 
proportion of cases, most of which are female, the onset is 
after 60 years of age.41 The youngest reported age of onset 
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103 
is 13 years. 
Neuropathology of TSP 
. . . 40 42 
Autopsy studies performed on TSP cases in Jamaica, ' 
38 43 44 . 
South India and the Seychelles ' have revealed similar 
findings. Pathology typically includes a chronic 
meningomyelitis with perivascular cuffing, hyaline arteriolar 
thickening (involving primarily the spinal cord but with 
minimal changes in the midbrain, cerebellum and the cerebrum), 
and a reactive astrocytic gliosis. There is also 
demyelination and axonal degeneration, mainly in the pyramidal 
tracts but also in the dorsal columns, spinocerebellar tracts, 
and less commonly, the spinothalamic tracts. The auditory and 
optic nerves may also be involved. 
119 
A study by Moore et al has demonstrated the presence of 
HTLV-I p19 core protein, a predominance of 
suppressor/cytotoxic T-cells, and the expression of class I 
major histocompatibility antigen in the spinal cord lesions of 
TSP. It is proposed that the mixed picture of demyelination 
and axonal loss with secondary tractal degeneration is a 
result of the lysis of the myelin sheath and eventually the 
axon by the action of cytotoxic T-cells, either directly or 
via the release of cytokines. 
Etiology of TSP 
In the past, various etiologic theories have been 
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proposed for TSP. The presence of treponemal antibodies in 
. . . . . 45 46 
the sera of a high proportion of TSP patients in Jamaica ' 
47 . ... 
and Colombia, areas hyperendemic for yaws and syphilis in the 
past, raised the question as to whether TSP is a late 
manifestation of yaws or syphilis. 
There has also been an increased incidence of serum 
antibodies to Borrelia burgdorferi (the etiological agent of 
4S 35 
Lyme disease) in patients from Jamaica and the Seychelles. 
The significance of this finding is unknown. 
The agent most strongly linked to TSP, however, is the 
human T-lymphotropic virus type I (HTLV-I). HTLV-I serum 
antibodies were initially reported in a high proportion (68%) 
of TSP patients by Gessain et al in 1985. This finding was 
. 29 49 
eventually confirmed ' and lead to the discovery of HTLV-I- 
positive (in sera and cerebrospinal fluid-CSF) TSP cases in 
Jamaica, 39,50 Colombia, the Seychelles,36 Trinidad,31 the Ivory 
Coast,53 Senegal,54 Peru,37 Chile,55 French Guyana,30 France,54 the 
Solomon islands,56 the Dominican Republic,104 Panama,105 in 
immigrants from the Caribbean to the UK,57 and as the present 
study shows, in Barbados. 
A chronic progressive myelopathy very similar to TSP, 
with 100% associated HTLV-I serum and CSF positivity, has been 
described in southwestern Japan by Osame et al. 58,59 This 
disease has been called HTLV-I associated myelopathy (HAM). 
An autopsy report of one HAM patient revealed perivascular 
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lymphocytic infiltration, with a prominent hyaline 
degeneration of the vascular media and adventitia, and 
leptomeningeal thickening. These findings are virtually 
identical to those found in TSP patients. Differences between 
these two disorders include frequent CSF pleocytosis, good 
response to corticosteroids, and a younger mean age of onset 
. 41 
in HAM (37 years as compared with 42 years) . More recently, 
however, the study of additional cases seems to have narrowed 
the differences and HAM and HTLV-I-associated TSP are 
considered to be the same disorder by some authors.114 
. . . . . . 59 
HTLV-I infection is endemic in Africa, southern 
Japan,60'61 the southeastern United States,62 the Caribbean 
basin,63 Alaska,64 Papua, New Guinea,65 Spain,66 and southern 
67 68 
Italy. ' Transmission of the virus seems to be via intact 
cells, and sexual contact, especially from male to female, has 
been implicated in its horizontal spread.62#69,70'71 Vertical 
transmission transplacentally,72 intrapartum,69 and via breast 
milk73 75 has also been suggested. 
The lymphotropic effect of HTLV-I is well known. The 
virus was first isolated in 1978 to 1979 from two black 
American patients: one with cutaneous T-cell lymphoma 
diagnosed as mycosis fungoides76 and one with Sezary T-cell 
leukemia.77 The virus was also isolated from Japanese patients 
with adult T-cell leukemia/lymphoma (ATLL), an aggressive T- 
. . . . . 79 
cell leukemia first identified and characterized in Japan. 
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Since that time HLTV-I associated ATLL has been noted in 
several groups of patients, including a series of patients of 
80 
West Indian heritage. In retrospect, the clinical features 
of the original two patients were more typical of ATLL. The 
chance of developing ATLL after seroconversion seems to be 
81 
low: 0.1 to 0.01%. 
In addition to being lymphotropic, however, the data now 
suggest that HTLV-I does have neurotropic potential. This is 
significant, since for the first time evidence is provided for 
a causative link of a human retrovirus to a chronic 
neurodegenerative disorder in humans. This is further 
supported by the isolation of the virus from the sera and CSF 
82 
of Jamaican and Colombian patients with TSP, from the CSF of 
83 
a patient with HAM, and from the sera and CSF of three family 
members with TSP.103 
Two other related but distinct human retroviruses, HTLV- 
II and HTLV-V, have been discovered. HTLV-II was isolated in 
1982 from a patient with a T-cell variant of hairy cell 
116 
leukemia, while HTLV-V was isolated in 1987 from a patient 
with cutaneous T-cell lymphoma/leukemia.117 There has been no 
indication to date that either virus has neurotropic 
potential. 
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Signs and symptoms of MS 
Multiple sclerosis, characterized pathologically by areas 
of demyelination and sclerosis in the central nervous system, 
has been described as having dissemination of lesions in both 
time and place. The course of the disease is unpredictable 
but the usual patterns are: benign (20% of patients), 
characterized by few exacerbations and near complete 
remissions; exacerbating-remitting (25% of patients), with 
more frequent early exacerbations and less complete 
remissions; chronic-relapsing (40% of patients), with fewer 
remissions and increasing disability as the disease 
progresses; and chronic-progressive (15% of patients), 
characterized by gradual onset and steady progression of 
. 101 
symptoms. 
Symptoms usually occur acutely and last for weeks or 
longer but can also last for a few minutes to hours. They 
include spastic muscle weakness, ocular disturbance, urinary 
disturbance, gait ataxia, paresthesiae, dysarthria or scanning 
speech, mental disturbance, pain, vertigo, dysphagia, 
convulsions, decreased hearing, and tinnitus. The signs 
include spasticity and/or hyperreflexia, Babinski sign, absent 
abdominal reflexes, dysmetria or intention tremor, nystagmus, 
impairment of position and vibration senses, impairment of 
pain, touch, and temperature sensation, facial weakness, and 
changes in state of consciousness. 
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The standard for evaluating disability in MS has become 
the Disability Status Scale by Kurtzke.120,121 The scale was 
developed in 1953-4 in response to a need to evaluate the 
efficacy of a new treatment for MS and has since undergone 
modification. 
Demographics of MS 
MS has traditionally been regarded as a disease of 
temperate regions. It is rarely reported in equatorial zones 
and increases in frequency with latitude in both hemispheres. 
There is a prevalence rate of 50 to 100 cases per 100,000 
population in temperate zones with the highest rates 150 cases 
per 100,000 being reported in the Shetland and Orkney Isles 
off the coast of northern Scotland. There has been a dramatic 
rise in MS cases in the tropical island of Barbados since the 
first recorded one in 1961. This is further examined in the 
discussion section. 
MS has a predisposition for the female sex with a female 
to male ratio of 1.5 to 1. With later onset, however, the 
ratio is closer to 1 to 1. Symptoms typically occur between 
20 and 40 years of age. Onset of symptoms before age 10 and 
after age 60 is rare. 
Neuropathology of MS 
There are usually several small areas of discoloration in 
the cerebral hemispheres particularly in the white matter and 
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periventricular areas. When defined with myelin sheath 
stains, these regions correspond to areas of demyelination. 
Sharply circumscribed plaques of varying sizes are scattered 
throughout the brain and spinal cord but tend to be grouped 
around the lateral and third ventricles. Lesions result from 
partial or complete destruction of the myelin, a lesser degree 
of damage to the axis cylinders or neurons, proliferation of 
glial cells and changes in blood vessels. Compound granular 
cells laden with cholesterol esters are present in the 
lesions, in the perivascular spaces of the vessels and in the 
tissue adjacent to them. Small lesions may be found in the 
gray matter and in the region between the gray and white 
matter. 
122 
The results of a study by McCallum et al suggest that 
the ratio of T-cell subsets is important in the evolution of 
the plaque margins. It was found that the numbers of both 
helper-inducer and cytotoxic-suppressor T-cells peaked at the 
edges of the plaques and that fewer cytotoxic-suppressor T~ 
cells were found in the normal appearing areas outside active 
plaques than equivalent areas outside inactive plaques. Their 
conclusions are that these findings, together with similar 
ones in experimental allergic encephalomyelitis suggest that 
plaque expansion depends on helper-inducer cell dominance at 
the border and that controlled disease is associated with 
cytotoxic-suppressor cell dominance in non-plaque areas. 
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Etiology of MS 
Two major theories about the pathogenesis of MS have been 
proposed. The first relates to an infection with a long 
incubation period. Organisms that have been suspect in the 
past include spirochetes, rickettsia, protozoa, and various 
types of viruses including rabies, herpes simplex types I and 
II, corona, canine distemper, and measles virus. Ever since 
. . . 123 
a report was published by Adams and Imigawa in 1962 
indicating that the average titer against measles was elevated 
in a group of MS patients, this virus has been a favored 
etiological agent of MS. Subseguent studies including one by 
124 . 
Brody et al have shown that unaffected siblings of MS 
patients (including twins) also had elevated antibody titers 
against a variety of viral agents possibly reflecting the 
individual's HLA type and that the epidemiology of the measles 
virus was not consistent with that of MS. 
Another theory implicates altered immune regulation, 
i.e., either increased immune responsiveness or a decreased 
suppression of the immune response to infection. Certain 
histocompatibility types associated with MS in northern 
populations are also believed to control immune 
responsiveness. 
There is also controversial evidence that HTLV-I or an 
HTLV-I-like virus may play a role in some cases of MS. The 
idea was first suggested by Koprowski et al when positive 

16 
serum HTLV-I antibodies titers were found in 7 of 17 patients 
34 
with MS in Key West, Florida. Subsequent reports failed to 
85 ■ 89 
corroborate this finding but 25% of a group of 68 Japanese 
patients with MS were found to have low-level positive serum 
. . 90 
HTLV-I antibody titers. Another study showed that the sera 
of 11 of 46 Japanese patients with MS contained antibodies 
against group specific proteins but not against envelope 
. 91 
proteins of HTLV-I, suggesting the involvement of a very 
similar but not identical virus. There have also been recent 
reports of the identification by polymerase chain reaction 
(PCR) of sequences homologous to HTLV-I DNA from patients 
. 92 93 . . . . 
with MS. ' Other studies using this sensitive method to 
detect and amplify low concentrations of viral DNA have not 
. . 125 
reproduced these findings. 
The positive findings may be explained by an overly 
sensitive test. Assuming that the results are real, it is 
also possible that evidence of HTLV-I in isolated MS cases may 
be coincidental. As noted in the discussion section, the 
issue is complicated by the fact that TSP and the chronic 
progressive form of MS share common clinical features. Thus, 
there exists a real potential for misdiagnosis. Laboratory 
data have been incorporated into the diagnostic criteria for 
126 
MS developed by Poser et al 
The role of HTLV-I and possibly other related 
retroviruses in the etiology of chronic neurodegenerative 
- 
17 
disorders remains to be elucidated. It is probable, however, 
that we are on the brink of new discoveries that will lead to 
a much clearer understanding of the mechanisms, and 
eventually, the prevention and treatment of these disorders. 
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MATERIALS AND METHOD 
Geographical and historical aspects 
Barbados, at 13° 10* north latitude and 59° 35' west 
longitude, is the easternmost of the group of Caribbean 
islands called the Windwards which begin with Martinique and 
stretch south to Grenada (see figure 3). Unlike many of the 
other Caribbean islands, it is not of volcanic origin, but 
consists geologically of a limestone base with an overlying 
coral cap. The rainwater quickly percolates through this 
natural filter resulting in both an absence of rivers and an 
extremely pure water supply. The highest peak is 1,105 feet. 
The weather is delightfully tropical with a high number 
of hours of sunshine per year tempered by northeast trade 
winds and with a humidity between 60 and 7 5%. The annual 
rainfall varies from about 40 inches in some coastal areas to 
90 inches in the central ridge area and the temperature ranges 
from a low of about 7 0°F to a high in the 9 0's. 
Its landscape is one of contrasts: the rugged cliffs of 
the east coast; the sandy beaches of the west; the expansive 
sugarcane fields; and the busy capital of Bridgetown (in the 
parish of St. Michael), home to almost 40% of the island's 
population. 
Originally populated by the Arawaks, Barbados was 
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discovered by the Portuguese in the 16th century but remained 
uncolonized until it was claimed by the British in 1625. 
Independent since 1966, Barbados has a unique place in 
Caribbean history in that it has been colonized by only one 
nation, Britain, from 1625. The main industries are sugar and 
tourism. The population of 250,000 is mainly of black African 
ancestry (92% black; 4% white; 4% mixed: population census 
1970) and with an area of 166 square miles Barbados has one of 
the highest population densities in the world. 
Study population 
This study was begun in June 1988 at the Queen Elizabeth 
hospital in Bridgetown, Barbados, and continued at the 
laboratory of Epidemiology and Public Health, Yale University 
School of Medicine. 
The initial sample size was 6 persons diagnosed with 
tropical spastic paraparesis (TSP) and 15 persons diagnosed 
with either 'clinically definite' or 'probable' multiple 
sclerosis (MS). 
Subjects were found from a pool of cases most of which 
were previously diagnosed by three clinicians at the hospital. 
Using hospital records, an energetic effort was made to 
contact the subjects by telephone and by mail. Owing to the 
inevitable loss to follow-up by death, change of address, and 
change of telephone number many were not contacted. Of those 
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contacted, two did not consent. 
At the end of 9 weeks, the clinical data on the cases 
were reviewed by Dr. George Nicholson and the investigator, 
and the designations 'MS' and 'TSP' revised using specific 
clinical criteria (see tables 1 and 2) . One TSP case and 2 MS 
cases (the terms 'TSP cases' and 'MS cases' refer to persons 
diagnosed with TSP and MS) were discarded since it was felt 
that there was insufficient evidence to make a diagnosis. In 
addition, one TSP case was reclassified 'MS'. The final 
sample size was thus 4 TSP cases and 14 MS cases. Three 
relatives of MS cases also consented to participate. 
All cases were matched with controls according to sex and 
age (within 2 years except in 3 pairs, whose age differences 
were 3, 4 and 5 years respectively). Controls were sought 
either from the patients hospitalized in the medical and 
surgical wards, or from the outpatients who visited the 
hospital. Conditions afflicting the controls were unrelated 
to either TSP or MS. 
Method 
Appointments were scheduled after oral consent was 
obtained (see appendix 1 for Information Sheet) and each MS or 
TSP case was asked guestions from a previously designed 
questionnaire (see appendix 7) aimed at identifying both risk 
factors for the diseases and characteristics and symptoms of 
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the cases. The degree of incapacitation of some of the 
neurological subjects was severe enough to preclude a hospital 
visit. In these instances they were visited in their homes by 
the investigator. 
From each case, the investigator collected 20 ml of blood 
by venipuncture using 2 vacutainers and 19- or 22-gauge 
needles. One tube was drawn for the purpose of antibody 
testing and the other (heparinized) for the purpose of 
isolation and culture of peripheral blood lymphocytes. 
At the end of each interview cases were asked if they 
would consent to having the investigator invite their close 
relatives (parents, if alive, and one sibling) to participate 
in the study. 
Controls were also interviewed and one vacutainer of 
blood drawn by venipuncture for the purpose of antibody 
testing. All questionnaires and blood tubes were coded to 
ensure confidentiality. 
Under sterile conditions the heparinized blood was added 
to lymphocyte separation fluid and centrifuged. The isolated 
lymphocytes were purified by differential centrifugation and 
then incubated with RPMI-1640 growth medium at 37°C. 
Periodically, medium was added to the cultures (see appendix 
8 for lymphocyte isolation procedure). 
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Serology and analysis 
The blood drawn for antibody testing was allowed to clot 
and the sera frozen for treponemal, Borrelia burgdorferi, and 
HTLV-I antibody testing (see appendix 2 for preparation of 
samples for antibody testing). The Venereal Disease Research 
Laboratory (VDRL) test, the fluorescent treponemal antibody 
absorbed (FTA-ABS) test and the Treponema pallidum 
hemagglutinin antigen (TPHA) test were done at the Sir Winston 
Scott Polyclinic in Barbados by C. Lucas, medical laboratory 
technologist (see appendices 3, 4 and 5 for protocols for the 
VDRL, FTA-ABS and TPHA tests, respectively). 
Frozen samples were sent to the laboratory of Dr. Francis 
Black at the Epidemiology and Public Health department at Yale 
University School of Medicine. HTLV-I antibody screening was 
done using a commercial enzyme-linked immunosorbent assay 
(ELISA) by R. Capper, laboratory technician (see appendix 6 
for ELISA protocol). Confirmatory Western blot analyses were 
performed in the laboratory of Dr. Clarence Gibbs at to 
National Institutes of Health (NIH) in Bethesda, Maryland (see 
29 
Vernant et al for Western blot protocol). 
Tests for IgG and IgM antibodies to Borrelia burgdorferi, 
the agent of Lyme disease, were done by ELISA in the 
laboratory of Dr. S. Malawista at Yale University School of 
Medicine by S. Cretella, laboratory technician (see Craft, et 
al100 for the protocol for measuring antibody to the Lyme 
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disease spirochete). 
Clinical data from hospital records and the data from the 
questionnaires were coded and analyzed with the aid of the 
Statpak Gold computer program. 
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RESULTS 
Age and sex distribution (see figures 1 and 2, and table 3.) 
The age of onset of symptoms in TSP patients ranged from 
22 to 47 years with a mean of 38.25 years. This is guite 
similar to the mean noted in TSP patients from Jamaica (39 
years40) and Martinigue (40 years29) and marginally less than 
that in patients from the Seychelles (42.5 years35) and 
Colombia (46.5 years33). In MS patients, the range of age at 
onset of symptoms was 19 to 39 years with a mean of 3 0.4 
years. Again, this mean is similar to that of 32 years noted 
. . 101 
in the literature. The mean age of onset of both diseases 
was lower in the female than the male patients: 31.5 and 45 
years respectively for TSP and 28.1 and 34.6 respectively for 
MS. A female to male ratio of 1.8:1 was obtained for the MS 
patients while the sexes were egually represented in the TSP 
patients. The mean duration of illness was slightly less in 
the TSP patients than in the MS patients: 6.25 years (range 4 
to 12 years) as compared with 8.2 years (range 1 to 16 years). 
Residence and ethnicity 
All 4 TSP patients were black Barbadians while of the 14 
MS patients, 9 were black Barbadians, 2 were white Barbadians, 
1 was of mixed ethnicity, and 2 were British-born whites who 
had been residing in Barbados for more than 6 years. With the 
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exception of 3 MS patients who were living in Canada, the UK 
and Australia respectively, all of the patients were residing 
in Barbados at the time of onset of symptoms. The most 
populous parish of St. Michael (about 40% of the population) 
was heavily represented, with 2 (50%) TSP cases and 6 (54% of 
11) MS cases (see figure 3). 
Travel history (see table 4) 
Positive travel histories were obtained for almost all 
patients. Only 3 MS patients had never left the island of 
Barbados. A negative travel history was obtained in 7 MS 
controls. All TSP patients had travelled outside of Barbados 
and 1 TSP control had not. Countries visited included other 
Caribbean islands, the UK, Canada and the USA. 
Social characteristics (see table 4) 
All questions were asked in reference to the time of 
onset of the symptoms of the disease. 
A very diverse range of occupations was noted for both 
groups of patients. The TSP group included a mechanic, cook, 
accountant and laborer, and the MS group included a plumber, 
seamstress, production manager in an electronics plant, 
engineer, cook, accountant, day-care worker, barmaid, bank 
teller, airline hostess, homemaker, two teachers, and one 
unemployed person. 
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Two TSP patients and all TSP controls were non-smokers, 
and 2 TSP patients were heavy smokers. More than half of the 
MS patients, 9, and 12 MS controls were non-smokers. Half of 
the TSP patients reported slight consumption of alcoholic 
beverages (two drinks or less per week) while one was a 
teetotaler and the other a heavy drinker (more than 10 drinks 
per week) . Of the TSP controls, half were slight drinkers and 
half were moderate to heavy drinkers. Eleven (79%) of the MS 
patients and the same number of controls were either 
teetotalers or slight drinkers. The other 3 were moderate to 
heavy drinkers. When compared with controls, no significant 
difference in smoking or drinking habits was noted. 
The household size for the TSP patients ranged from 2 to 
5 members with a mean of 3. The mean household size for MS 
patients was slightly greater at 3.9, with a range of 1 to 11 
members. 
Past medical history 
One of the women with TSP had had 5 pregnancies with 3 
abortions while the other was nulliparous. The total number 
of pregnancies for 9 women with MS was 17 (mean 1.89) and two 
had had one or more abortions. 
Only 2 patients reported positive blood transfusion 
histories: one TSP patient (who was also HTLV-I positive), and 
one MS patient. Past medical histories were, in general, non- 
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contributory. 
Environmental toxins 
Most patients reported only rare or occasional exposure 
to pesticides, disinfectants, or other potentially neurotoxic 
chemicals. Three (21%) MS patients, however, had had 
significant contact with dyes, insecticides, and battery 
fluids, respectively for some years. 
No TSP patient reported a consumption of cassava greater 
than once every few weeks. Most of the MS patients reported 
the same, but two (14%) had been consuming cassava about once 
or twice a week. The cassava that was consumed was usually of 
the sweet and not of the bitter variety which has been 
associated with neurotoxicity when improperly prepared and 
comprising a large portion of the diet. The preparation of 
the bitter variety entails grating the cassava, washing away 
the poisonous juices, and drying the meal. There was no use 
of peas of the Lathyrus family. 
There seemed to be minimal use of folk medicines and 
"bush teas" but one MS patient reported the frequent use of 
aloes and another, the frequent use of homeopathic "powders 
and pills." 
Nutrition 
All of the patients were clinically well nourished. Fish 
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played a significant role in the diet of most patients but 
other types of seafood were consumed occasionally or rarely. 
Other factors 
All TSP patients had had some exposure to pets and/or 
farm animals in the recent past (within the previous 10 years) 
compared with 10 (71%) MS patients. Another 3 (21%) MS 
patients had had some exposure in the more distant past while 
one MS patient reported no contact with pets or farm animals. 
Data analysis 
Using the Statpak Gold statistical analysis package, the 
data obtained from the guestionnaires were analyzed. The type 
of subject (case, control and sibling) was cross-tabulated 
with the coded responses to the guestions and the chi-sguare 
values obtained. In general, no significant difference was 
obtained in the responses and characteristics of cases as 
compared with controls. 
One significant result (p<0.05) was noted in the cross¬ 
tabulation of type of subject versus the use of medications in 
the 6 months before onset of disease (cases) or in the 6 
months previous to the administration of the questionnaire 
(controls). Controls were more likely to have used 
medications than cases. This is explicable by the fact that 
before the onset of TSP or MS, most of the cases were 
perfectly healthy, while the controls, drawn from a hospital 
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population, tended to have an underlying condition requiring 
the use of one or several types of medication. Memory may 
have also played a role since onset of disease sometimes 
preceded administration of the questionnaire by several years. 
Clinical characteristics (see table 3) 
TSP: 
The clinical course of the disease was unremitting in 3 
(75%) TSP patients and uncertain in 1 (25%). Two patients 
(50%) were able to walk unaided while the others required 
support. All patients reported leg weakness and dysesthesiae 
and 3 experienced constipation. Bladder dysfunction and 
blurred vision/diplopia were each reported by 2 patients. 
MS: 
The course of 10 (71.4%) MS patients was significant for 
remissions/relapses while 1 patient had a progressive course. 
The course of 3 patients was uncertain. Nine (64.3%) patients 
were ambulatory, 4 (28.6%) required support and 1 was 
incapacitated. The most common symptom, reported by 12 
(85.7%) patients, was blurred vision or diplopia. Ten (71.4%) 
patients had lower limb weakness and 8 (57.1%) lower back 
pain. Lower limb dysesthesiae and bladder dysfunction were 
each reported by 7 (50%) MS patients while leg cramps and 
constipation were reported by 6 (42.9%) and 4 (28.6%) MS 
patients respectively. 
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Serology (see table 5) 
HTLV-I: 
Serum samples from MS and TSP cases and controls were 
tested with the Retro-Tek HTLV-I ELISA kit manufactured by 
Cellular Products, Inc., Buffalo, New York. Results of the 
ELISA test revealed 11 positive samples (3 TSP cases, 1 MS 
case, 2 TSP controls, 4 MS controls, and 1 MS relative) and 7 
borderline samples (4 MS cases, 1 TSP control, and 2 MS 
controls) . One of the samples (an MS case) with borderline 
results retested positive. Western blot confirmation was 
obtained with 2 TSP samples. Sera from these 2 patients 
demonstrated antibodies to the gag-encoded pl9, p24, p33, p36, 
and the env-encoded gp46. None of the sera from MS patients 
or TSP and MS controls was positive in the Western blot assay. 
Treponema pallidum: 
The VDRL test was done using the Bacto VDRL antigen 
manufactured by Difco Labs., Detroit, Michigan. Only one 
sample, that from an MS control, was reactive (1:4). 
Confirmation was obtained with the TPHA test using the kit 
manufactured by Fujirebio Inc., Tokyo, Japan. Another sample, 
an MS case, was 'rough negative' on the VDRL but was non¬ 
reactive on the FTA-ABS test (Difco Labs). 
Borrelia burgdorferi: 
All sera were tested for IgG and IgM antibodies to the 
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agent of Lyme disease. None of the samples had elevated 
titers. 
The attempt at culturing the isolated lymphocytes was 
unsuccessful because of contamination of the cell cultures. 
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DISCUSSION 
Estimation of the number of TSP patients in Barbados 
Prior to conducting the study, a gross estimate of the 
number of TSP patients in Barbados was made by using the then 
current prevalence ratio of Martinique. Martinique is 110 
miles from Barbados and has an HTLV-I positivity rate of 4% in 
blood donors younger than 60 years of age30. This 4% rate is 
similar to the HTLV-I positivity rate in the general Barbadian 
. 94 
population . Thus, with a TSP prevalence of 11.8 per 100,000 
in Martinique30 (population 328,566) and with a Barbadian 
population of 250,000, the number of patients with TSP was 
estimated at 30. A sample size determination was also done 
using the following calculations. 
Determination of sample size 
For a matched case-control study, as discussed by 
118 
Schlesselman, for a specified a and 6, the number of 
exposure-discordant pairs m (pairs of cases and controls that 
differ with respect to the risk factor - in this case, HTLV-I 
antibody) required to detect a relative risk R is given by: 
m = [zff/2 + zB yp 7(1 - P)]2 / (P - 1/2)2 
where P ~ R / (1 + R) 
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The relative risk R was first determined by calculating the 
odds ratio of TSP. The odds ratio can be calculated based on 
results obtained in Martinique. A 2x2 table can be drawn: 
HTLV-I 
+ Total 
Case 53 7 60 
Control 154 1059 1213 
The odds ratio is given by: (1059 x 53) / (154 x 7) = 
52.1 
Since TSP is a relatively rare disease, the relative risk 
# 
can be estimated to equal the odds ratio, so 
for P = 52.1 / (1 + 52.1) = 0.98 
za (a error) = 1.645 (95%, one-tailed) 
zB (6 error) = 1.282 (90%, one-tailed), 
m = [1.645/2 + 1.282 /0.98 /(l - Q.98)]2 / (0.98 - 0.5)2 
= 4.357 
Thus 5 exposure discordant pairs are required for proper 
use of the McNemar statistical test. 
If pe represents the probability of an exposure- 
discordant pair, the total number of pairs M required to yield 
m discordant pairs is M = m/pe and pe can be found from: 
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Pe * (Po <3l + Pi <3o> 
where p0 is the estimated proportion of exposed controls in 
the target population (4% of the general Barbadian population 
have antibodies to HTLV-I)94, q0 = 1 - p0 and q, = 1 - P-j. 
p1 is the estimated proportion of exposed cases and is 
given by: 
Pi = P0 R / [1 + Po (R - 1) ] 
Thus p1 = 0.04 x 52.1 / [1 + 0.04 (52.1 - 1) = 0.685 
and pe = (0.04 x 0.315) + (0.685 x 0.96) = 0.67 
and M = 5/0.67 = 7.46 
Thus 8 case-control pairs are required to yield 4 
exposure-discordant pairs. 
With a total of 4 pairs of cases and controls and with 2 
pairs that differed with respect to HTLV-I positivity in this 
Barbadian study, i.e half the required number, statistical 
analysis with the McNemar's will not be feasible. 
Power of the study 
The power of this matched study can be calculated from: 
zB = [—z„/2 + (P - 1/2) /m] / yp 7(1 - P) 
where za = 1.64 5, m = 2 (there are 2 exposure-discordant 
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pairs in this study), and P = 0.98 as calculated previously. 
Thus, 
ZB = [-1.645/2 + (0.98 - 0.5) J2] / 70.98 7(1 - 0.98) = -1.03 
and the power can be determined from the tables of normal 
distribution by finding the probability that zB is not 
exceeded. 
Hence the power of this study is P (Z < -1.03) or 0.152 
and there is a 15.2% probability of finding that the sample 
estimate of relative risk differs significantly (a = 0.05) 
from unity. 
TSP in Barbados 
The cases diagnosed as TSP in Barbados are not epidemic. 
Malnutrition, cassava neurotoxicity and lathyrism are not 
relevant since no subject was clinically malnourished and no 
one reported consumption of peas of the Lathyrus family or 
significant consumption of the bitter variety of cassava. As 
mentioned previously, the 4 cases of TSP reported here are 
similar, both with respect to the demographics of the patients 
and to the clinical characteristics of the disorder, to those 
endemic cases reported in the literature. 
With an estimated TSP population in Barbados of 30 (based 
on data from Martinigue), the yield of 4 cases in the current 
study suggests that some cases are unrecognized. A 
coordinated effort from the private physicians and the several 

36 
polyclinics throughout Barbados would probably identify cases 
that would otherwise not be followed at the Queen Elizabeth 
Hospital. 
HTLV-I serology in TSP patients 
Even without formal analysis, a 50% HTLV-I antibody 
positivity in TSP patients as compared with 0% in controls 
does suggest an etiological role of HTLV-I in the pathogenesis 
of TSP. This HTLV-I antibody positivity rate compares with 
one of 91% (in sera) and 84% (in CSF) in Jamaican TSP 
patients,107 88% (in sera) and 100% (in CSF) in TSP patients 
from Martinique, 108 8 6% (in sera) and 100% (in CSF) in 
109 
Trinidadian TSP patients, and 82% (m sera) and 100% (in 
. .104 
CSF) in TSP patients from the Dominican Republic. 
In any event, these rates raise the question: why is 
there not 100% HTLV-I positivity in the sera of TSP patients? 
One possibility is that the IgG antibodies in the sera of 
certain cases may be of such low titers that the sensitivity 
of the tests currently used may be inadequate. Fresh samples 
and proper storage of the samples also seem to be important as 
evidenced by the fact that when 2 3 of the most recently 
collected Jamaican samples were tested (within 4 weeks), 
positivity in sera increased from 91% to 100% and positivity 
• . 107 
in CSF increased from 84% to 96%. The samples in this 
Barbadian study were properly stored and fresh when tested. 
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The possibility also exists that antibodies to HTLV-I are 
only produced at certain intervals during the course of the 
disease. In fact, it is quite likely that the symptoms of TSP 
are not necessarily caused by a persistent viral infection, 
but rather by a chronic immune-mediated 
encephalomyeloneuritis. This has been suggested by Vernant et 
29 , 
al. As mentioned previously, a virus-induced, cytotoxic T- 
cell mediated mechanism in which lysis of the myelin sheath 
and axon results from the effect of the suppressor/cytotoxic 
119 
T-cells has been proposed by Moore et al. This is based on 
the findings of a predominance of suppressor/cytotoxic T- 
cells, HTLV-I core protein and the expression of class I major 
histocompatibility antigen in spinal cord lesions. 
Localization of the core protein to inflammatory cells 
suggests that the virus may gain entry into the CNS via these 
cells. Since, however, some parenchymal cells were also 
positive for viral antigen, a direct primary infection of 
intrinsic CNS elements cannot be excluded. 
An immune-mediated mechanism has also been suggested 
based on the presence of skin lesions suggestive of immune- 
complex vasculitis and lymphocytic pulmonary alveolitis in TSP 
. . . 110,111 
patients. 
Vernant et al have also suggested that the HTLV-I- 
negative group of patients in their study may represent a 
different etiopathological syndrome since a comparison of this 
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group with the HTLV-I-positive group revealed a difference in 
the sex ratio, the mean age of onset, and the characteristics 
of the symptoms. Of interest is a comparison of the HTLV-I- 
positive group with the HTLV-I-negative group of TSP patients 
in the current Barbadian study which reveals a similar 
difference in the mean age of onset, despite the small sample 
sizes (2 in each group). The mean age of onset in the HTLV-I- 
positive group was 44 years while that of the HTLV-I-negative 
group was 32.5 years. This compares with a mean of 45 years 
in the former group and one of 35 years in the latter group in 
the TSP patients from Martinique. 
It is well to bear in mind that the epidemic form of TSP 
seems to be caused by more than one factor. The TSP seen in 
HTLV-I negative patients may have some other as yet 
unidentified factor as an etiological agent. 
Another important question is: why don't all persons with 
antibodies to HTLV-I develop TSP/HAM (or ATLL)? The answer 
may lie in a genetically predetermined susceptibility to HTLV- 
I. A preliminary study of the HLA haplotypes in 63 patients 
with HTLV-I-associated TSP in Martinique revealed an increase 
in the frequency of B7 and CW7 antigens in comparison with the 
. . . . 112 
HTLV-I-positive asymptomatic population. However, when 
corrected for the number of antigens tested, this finding was 
not significant. A study in Japan has also reported a link 
between certain HLA haplotypes and HAM in contrast to the HLA 
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. 113 
haplotypes found in the ATLL patients. 
These studies suggest that the development of a 
particular pathology in an HTLV-I-infected host is dependent 
on the HLA-related immune responsiveness of that host. 
Ijichi et al115 have hypothesized with respect to HAM 
patients, that 
the supply of infected (CD4 positive) T-cells 
from peripheral blood to CNS is primary for the 
development of CNS lesions. Following the 
expansion of infected T-cells with viral antigen 
presentation in the CNS, the propagation of immune 
responses, including responses of cytotoxic T- 
cells, B-cell activation, and microglial reaction, 
may occur on the basis of high-immune 
responsiveness against HTLV-I. 
They note that one of hallmarks of HTLV-I infection is 
the autologous proliferation response (APR) which is 
characterized by the spontaneous growth of infected T-cells 
and reactive proliferation of T-cells responding to HTLV-I 
infected lymphocytes in vitro. In their conclusion they state 
that 
We demonstrated the existence of serum 
factor(s) that inhibit APR in HAM patients. 
Furthermore, cerebrospinal fluid from HAM patients 
did not exhibit a significant inhibition of APRs. 
These data suggest the impermeability or 
hypopermeability of the blood-brain barrier to the 
serum inhibitor(s) and lead us to propose the 
hypothesis that an APR-like phenomenon occurs in 
vivo in the central nervous system of HAM 
patients. 
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MS in Barbados 
Multiple sclerosis has been diagnosed with a surprisingly 
high frequency in Barbados in the past decade (Sivarajan S, 
Evelyn SV, Fraser HS102) . MS typically affects patients in 
temperate climes and has been reported with rarity in the 
Caribbean.95 Sivarajan et al report with respect to Barbados, 
that 
there has been an eight-fold increase in the 
incidence of multiple sclerosis... over the last 25 
years, and particularly the last decade (22 or 58% 
in the last six years). 
In their discussion they cite several possible reasons 
for the increase in the incidence of MS, including increased 
risk through increased travel and exposure to northern 
environments, increased tourism with the compromise of 
function of MS patients in the hot climate, increased case 
finding due to increased interest in neurological disorders 
and improved referral and diagnostic practices, and 
overdiagnosis. 
In the present study, 14 patients with MS consented to 
participate. Of these patients, 3 did not spend their 
childhood years in Barbados. With MS and TSP sharing many 
characteristics in common, there is some potential for 
misdiagnosis specifically with the chronic progressive form of 
• • 101 
MS which occurs in 15% of MS cases. Both may have an 
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insidious onset and a slow progression with spasticity, 
hyperreflexia and leg weakness as major components of the 
disease. Supportive laboratory data (specifically examination 
of oligoclonal bands and increased production of 
immunoglobulin G) have been incorporated into the diagnostic 
126 
criteria for MS published by Poser et al, but even 
laboratory results may be unrevealing since oligoclonal bands 
in CSF fluid and abnormal cortical evoked responses may 
sometimes be seen in both disorders.106'57 
127 
Poser, Roman and Vernant have suggested that before a 
diagnosis of MS be changed to HTLV-I-associated chronic 
myelitis at least two of the following six abnormalities be 
present: clinical or electrophysiologic involvement of 
peripheral nerve or muscle (rare in MS); the presence of 
oligoclonal bands in the serum (considered to be evidence 
against MS); the presence in blood or CSF of lymphocytes with 
multilobed nuclei (adult T-cell leukemia cells) ; a positive 
serologic test for syphilis; the presence of the sicca 
syndrome; the presence of pulmonary lymphocytic alveolitis. 
In the present study, cases diagnosed as MS do not have 
a higher HTLV-I prevalence rate than the controls. Thus it is 
unlikely that the finding of a seemingly small number of TSP 
cases and a large number of MS cases relative to Martinique 
and Jamaica is due to misdiagnosis. Also, as noted of MS in 
Barbados by Sivarajan et al (unpublished) 
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the increasing incidence and prevalence of MS 
in Barbados is intermediate between equatorial or 
tropical countries and the temperate, developed 
countries. The clinical pattern and the course 
have a similar distribution to that in the 
literature for northern countries -- i.e. 61% 
generalized compared to 50% in the literature, and 
29% spastic (30-40% in the literature). There is 
no excess of the latter type as might occur in 
misdiagnosing a 'tropical spastic neuropathy' such 
as the Jamaican neuropathy as MS. 
There is an excess of Caucasian MS patients (28.6%) in 
the present study as compared with the general population 
(4%) , but this is not enough to explain the high MS rate. 
With the increased incidence of MS in Barbados, a tropical 
country with a population predominantly of African descent, 
and with the recent report of HTLV-I positive spastic 
paraparesis in patients of European, mixed Mestizo and 
Mapuches Indian descent in temperate Santiago, Chile,55 the 
geographic and ethnic scope of these two diseases has 
expanded. This overlap may increase the uncertainty of many 
diagnoses unless rigid criteria are defined and adhered to. 
This is evidenced by a case report of an Haitian patient 
diagnosed with TSP but with magnetic resonance imaging (MRI) 
studies showing lesions in the white matter of the brain and 
spinal cord identical to those seen in MS.96 As more physicians 
worldwide become aware of the widened distribution no doubt 
more 'atypical' cases of TSP and MS will be discovered. 
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HTLV-I serology in MS patients 
The absence of HTLV-I antibody in sera of MS patients 
85 ■ 89 
found in this study is similar to that in previous studies 
and does not support a role of HTLV-I in the pathogenesis of 
MS. The screening tests were done using a commercially 
prepared ELISA kit and the positive sera confirmed by Western 
blot analysis using HTLV-I p-24 purified antigen, antibodies 
to which have been shown to correlate highly with HTLV-I 
infection.97 
The lack of positivity must be interpreted with caution, 
however, since the commercially prepared ELISA has been 
criticized for lacking adequate sensitivity.84'98 However Koike 
et al, using autoradiography to increase the sensitivity and 
a combination of Western blotting and autoradiography with 
recombinant p-24 to increase the specificity, failed to detect 
89 
HTLV-I antibodies in sera of MS patients. Most of these 
latter sera were also drawn when the patients were not in 
remission so as to avoid possible periods of low antibody 
. 84 
levels as postulated by Koprowski. 
Lyme and Treponemal serology 
As noted previously, there have been some reports of 
increased antibodies to Treponema pallidum and Borrelia 
burgdorferi in the sera of patients with TSP. The absence of 
serum antibodies to either of these two organisms in TSP or MS 
patients in the current study argues against a role for them 
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in the pathogenesis of these two disorders in Barbados. The 
presence of antibodies against both HTLV-I and Treponema 
pallidum in TSP cases in a recent report from the Dominican 
104 . ... 
Republic may be coincidental but the possibility must be 
entertained that HTLV-I infectivity or pathogenicity may be 
enhanced by a cofactor. Treponema pallidum and other non¬ 
specific agents may fulfill this role. 
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CONCLUSION 
In conclusion, this study supports an etiological role 
for HTLV-I in cases diagnosed as TSP but not in cases 
diagnosed as MS in Barbados. Treponema pallidum and Borrelia 
burgdorferi do not seem to be associated with either of these 
two disorders as seen in Barbados. No other etiological 
factors are identified. 
The finding of a relatively small number of TSP 
patients in Barbados as compared with Jamaica and Martinique 
and that of a surprisingly high incidence of MS in a tropical 
island with a predominantly black population are of interest. 
These cannot be explained on the basis of misdiagnosis of 
cases since HTLV-I serum antibodies were not found in cases 
diagnosed as MS. It is tempting to speculate that a separate 
agent, possibly a retrovirus related to, but distinct from 
HTLV-I, may be in some way associated with the HTLV-I-negative 
cases of TSP and the cases of MS in Barbados. 
It is recognized that further work needs to be done in 
Barbados to determine the prevalence of TSP and to determined 
the significance of the findings of this study. Although 
HTLV-I is firmly established as the etiological agent of TSP 
there is a significant amount yet to be learned about the 
etiology of MS and the pathogenetic mechanisms of both TSP and 

46 
MS. 
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TABLES 
Table 1. 
Clinical diagnostic criteria for TSP (adapted from Roman et al36) 
1. A minimum of two of the following within 2 years of onset: 
Increased urinary frequency, nocturia or retention 
and/or severe constipation and/or impotence (in 
men) 
Leg cramps and/or low back pain 
Weakness of the lower extremities within 6 months 
of onset of the disease 
Complaints of numbness or dysesthesiae of the legs or 
feet 
2. Absence of a history of relapses 
3. Spasticity (clinical hypertonicity, hyperreflexia, clonus) 
of both legs, usually demonstrated by spastic gait. 
4. Absence of a sensory level. 
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Table 2. 
. . . . . . 99 
Clinical diagnostic criteria for MS 
Clinically definite: 
Consistent course 
Relapsing, remitting course; at least two bouts 
separated by at least one month 
Slow or stepwise progressive course for at least 6 
months 
Documented neurological signs of lesions in more than one 
site, of brain or spinal cord white matter 
Onset of symptoms between 10 and 50 years 
No better neurologic explanations 
Probable: 
History of relapsing, remitting symptoms but signs not 
documented and only one current sign currently 
associated with MS 
Documented single bout of symptoms with signs of more than 
one white matter lesion; good recovery, then variable 
symptoms and signs 
No better neurologic explanation 
Possible: 
History of relapsing, remitting symptoms without 
documentation of signs 
Objective signs insufficient to establish more than one 
lesion of central white matter 
No better explanation 

Table 3. 
Characteristics of TSP and MS patients 
TSP (N=4) MS (N=14) 
Average age of onset 
by sex M: 45, F:31.5 M:34.6, F:28. 
overall 38.25 years 30.4 years 
Range of onset age 22-47 years 19-39 years 
Duration of disease 4-12 years 1-16 years 
(mean= 6.25) (mean= 8.2) 
Female to male ratio 1:1 1.8: 1 
Lower limb weakness 4 (100%) 10 (71.4%) 
Gait 
walks unaided 2 (50%) 9 (64.3%) 
walks with support 2 (50%) 4 (28.6%) 
cannot stand or walk 0 (0%) 1 (7.1%) 
Lower limb cramps 0 (0%) 6 (42.9%) 
Lower limb dysesthesiae 4 (100%) 7 (50%) 
Lower back pain 3 (75%) 8 (57.1%) 
Bladder dysfunction 2 (50%) 7 (50%) 
Constipation 3 (75%) 4 (28.6%) 
Blurred vision/diplopia 2 (50%) 12 (87.5%) 
Course of disease 
Progressive/stable 3 (75%) 1 (7.1%) 
Remissions/relapses 0 (0%) 10 (71.4%) 
Uncertain 1 (25%) 3 (21.4%) 
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Travel, smoking and alcohol histories 
in TSP and MS cases and controls 
TSP MS 
Cases Controls Cases Controls 
* 
Travel history 
none 0 (0%) 1 (25%) 3 (21.4%) 7 (50%) 
slight 3 (75%) 2 (50%) 3 (21.4%) 6 (42.9%) 
moderate 1 (25%) 1 (25%) 2 (14.3%) 0 (0%) 
heavy 0 (0%) 0 (0%) 5 (35.6%) 1 (7.1%) 
★ ★ 
Smoking history 
none 2 (50%) 4 (100%) 9 (64.3%) 12 (85.7%) 
slight 0 (0%) 0 (0%) 2 (14.3%) 0 (0%) 
moderate 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
heavy 2 (50%) 0 (0%) 3 (21.4%) 2 (14.3%) 
Alcohol history0 
none 1 (25%) 0 (0%) 5 (35.6%) 8 (57.1%) 
slight 2 (50%) 2 (50%) 6 (42.9%) 3 (21.4%) 
moderate 0 (0%) 1 (25%) 2 (14.3%) 0 (0%) 
heavy 1 (25%) 1 (25%) 1 (7.1%) 3 (21.4%) 
Slight: 1-2 trips; moderate: 3-5 trips; heavy: > 5 trips. 
** 
Slight: < 2 cigarettes/day; moderate: 3-5/day; heavy: > 5/day. 
°Slight: < 2 drinks/week; moderate: 3-5/week: heavy: > 5/week. 
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Table 5. 
Summary of serological results 
Case 
Screening HTLV-I 
ELISA 
positive 
TSP 
(n=4) 
3 
(75%) 
MS 
(n=14) 
1 
(7.1%) 
Control 
TSP MS 
(n=4) (n=14) 
2 
(50%) 
4 
(28.6%) 
borderline 0 
(0%) (28.6%) 
1 
(25%) (14.3%) 
Final positive 
HTLV-I ELISA° 3 
(75%) (14.3%) 
2 
(50%) (28.6%) 
Positive HTLV-I 
Western blot 2 (50%) 0 (0%) 0 (0%) 0 (0%) 
Positive TPHA 0 (0%) 1 (7.1%) 0 (0%) 0 (0%) 
Positive B. 
Burgdoferi ELISA 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
After borderline samples were retested 
Relative 
(n=3) 
1 
(33.3%) 
0 
(0%) 
1 
(33.3%) 
0 (0%) 
0 (0%) 
0 (0%) 
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RESIDENCE AT ONSET OF DISEASE OF 
4 TSP AND 14 MS PATIENTS 
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Appendix 1 
INFORMATION SHEET 
You are invited to participate in a study of chronic 
neurological diseases. The purpose of this study is to identify 
certain factors that may cause these diseases. You have been 
chosen for the study either because you or one of your relatives 
has such a disease, or because you are free from it. 
Your participation will involve giving two small tubes of 
blood and being interviewed. If you are not a hospitalized patient 
you will be required to make a hospital visit which should take 
about one hour. Drawing blood may hurt slightly and you may get a 
small bruise. 
Various tests will be done on your blood. Your name will not 
be used to identify your sample and will not be used in records of 
the study. You will be identified only by a code number and your 
signature on this sheet will not be required. Because we will not 
have your name, you will not receive results of the tests. 
This study may be of no direct benefit to you but it may help 
us find out more about what causes certain neurological diseases 
and how they may be prevented. 
You are free to chose not to participate. You may not be 
familiar with some of the terms used on this sheet. Please feel 
free to ask about them or about anything else you are not sure of. 
You are welcome to take as much time as you need to decide. 
Signature of Principal Investigator Telephone 
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Appendix 2 
PREPARATION OF SAMPLES FOR ANTIBODY TESTING 
. Collect blood ('10 ml) in a vacutainer 
. Allow blood to clot by standing for at least 6 
hours at room temperature 
. Centrifuge at 2000 rpra for 5 minutes 
. Remove '1 ml of serum (supernatant) and freeze in 
vials for treponemal antibody testing 
. Freeze remainder of serum in serum tube for 
future antibody tests 
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VDRL TEST REAGENTS 
BACTO VDRL ANTIGEN 
BACTO VDRL TEST CONTROL SERUM SET 
9acto VDRL Antigen -s used for ;he VDRL 5iide quai-'ative 
quantitative) Test procedures as described m me Manual ot "es.'s 'or 
Syphilis 1969 
VDRL antigen, along -v11h others, s defined as a nom'eponema! 
antigen ■' As discussed m Syphilis a Synopsis, reactive nontreponemai 
fasts confirm the diagnosis -n me presence of early or ale les.on 
syphilis, offer a diagnostic clue m latent succtmicai syphilis are an ef 
'ective tool for detecting cases n epidemioiogic investigations and are 
superior to ihe treponemal test for following 'he response to therapy ' 
Nontreponemai antigen tests are not entireiv specific for syphms ncr oo 
they nave satisfactory sensitivity ,n an stages or syphii s Whenever 'he 
esults of a non’reponemal antigen ‘est disagree with tne '•timcai -m 
pression a treponema* an'igen ’est such as the FTA-ABS' :r mATTS 
should be performed 
TEST SUMMARY 
VDRL antigen s a sardioiipm-ieethin antigen So',ai ’^ o or 
inactivated serum ana VDRL antigen emuision preca ed mom VDRL an- 
cgen and VORL buffered sa-me are mixed win me aid of a rotating 
machine for a prescribed period of tine. During me m.xmg : me me 
lardioiipin-iecithm-coated cholesterol par'icies fioccu'ate m me 
^ esence of an antibody nke substance • reag = •'> mat s oresen' n sera 
from syphilitic persons and occas- onaliy .n sera or persons w-n ether 
acute and chronic conditions • 
Qualitative 'estmg is performed first an specimens Eacn se'um m3> 
produces a Reactive Weakly Reactive or -ough Non•'■eact-ve resu'' n 
the qualitative VDRL Slide Test «s retested Quantitatively t q an enq 
point titer 
REAGENTS 
Bacto VDRL Antigen contains 0 03 ’ > cardiotiom ana 0 9 1 - i.no'esreroi 
dissolved :n absolute aiconot with sufficient purified 'ec m.n 0 21 
± 0 01 ’ ■>> to produce standard reactivity it is prepared according to me 
directions given oy Hams. Rosenberg and Riedel ' Cardiolioin and 
'ecithm are prepared according ;o directions given by Pangbom • 1 Car 
diolipm is prepared under license from me New r'ork Stale Department 
of Health 
Bacto VDRL Buffered Saline <pH 6 0 r 0 1) for the preparation of tne 
VDRL Antigen emulsion contains 
0 037 g secondary sodium phospnate. annydrous. (A C.S ) 
0.170 g primary potassium phospnate -. A C S i 
10 0 g NaCi. (ACS. 
t 0 liter distilled water 
8acto VDRL Buffered Saline is a slight modification of the formulation 
given by Harris. Rosenberg and Riedel ' The formaidenyde has oeen 
omitted 
Bacto Nontreponemai Antigen Reactive Serum is a human serum stan¬ 
dardized to provide a reactive reading when tested according to the USR 
or VDRL ’est procedures 
Bacto VDRL Weak y Reactive Serum is a human serum standardized to 
provide a weanty reactive reading when tested according to the VDRL 
test procedure 
Bacto Nontreponemai Antigen Nonreactive Serum is a human serum 
standardized 'o provide a non reactive reading when tested accoramg to 
me USR or VDRL test procedure 
Bacto Aliquant Viai is an empty serum vial fittea with a split stopper ana 
screw cap it is for receiving anO storing aiiquants of rehyOrated control 
sera in amounts sufficient for one testing period 
Precautions 
Each human serum used m preparing the control serum contained m 
Bacto VDRL Test Control Serum Set has been screened for the presence 
of hepatitis B surface antigen Only sera exhibiting a negative reaction 
are used m preparing these reagents As an additional precaution the 
user should employ prooer and aseptic techniques in handling all 
human sera 
Before performing this test the user should be familiar with the contents 
of sections introduction and Appendix of the Manual ol Tests tor 
Syphilis 1969 
For in Vitro Diagnostic Use 
Rehydration and Storage 
On receipt, store the package of Bacto VDRL Antigen and Sacto VDRL 
Buffered Saune at room temperature When ready to use tne Bacto 
VDRL Antigen, pour the entire contents of the ampul into the Bacto 
VDRL Antigen Storage Vial provided m the box Cap the bottle tignny 
and store it m the dark at 15 • 30 C Withdraw antigen as reauired After 
the Dottle of Bacto VDRL Buffered Saline is ooened. it should be stored 
at 2 9 C between the periodic withdrawals of saline for preparing me 
emulsion Discard the Buffered Saline if mold or turbidity apoears 
i>e ■ nrpp :;>ntroi sera contained in Bacto VDRL rest Control Serum Se1 
are stored at 2 3C Renydrate me sera with 3 tii Sterne distiHea dr 
deionized water Transfer renvOratea sera that are n excess dt 'he first 
davsusentoa Bacto Aliquant Vial ana maintain at — 20 C forupto one 
month Do not 'haw ano refreeze. The expiry date of the aliquant is not 
to exceed 'he e«pirv date ot the original container 
SPECIMEN COLLECTION AND PREPARATION 
1 Obtain blood specimen and allow to clot Separate serum from me 
:iot bv centrifugation (1500 2000 rpm ‘or 5 minutes) 
2 inactivate serum specimen at 56 C for 30 minutes 
3 Centrifuge sera containing particulate debris prior to 'estmg 
4 Reinactivate, at 56 C for 10 minutes all sera to be tested subsequent 
to 4 hours alter original inactivation 
5 Cooi all sera io room 'emperature (23 29 C) prior to testing 
PROCEDURE 
Procedures as described nere are essentially (hose described m me 
Manual ol Tests lor Sypniiis US Department of Health Education ana 
Welfare •' 
Materials Provided 
Bacto VDRL Antigen with Bacto VDRL Buttered Saune 
Bacto VDRL Test Control Serum Set 
Materials Required But Not Provided 
Rotating machine adiustabie to '80 'pm circumscribing a circle '• 
n diameter on a horizontal plane 
Hypodermic needles without bevels for serum test i3 gauge, for 
spmai fluid 'est 21 or 22 gauge 
2 ' < 3 glass suae with 12 paraffin or ceramic rings approximately 
i4 mm m diameter tor serum test 
Agglutination shoe approximately 2 < 3 with concavities measuring 
>6 mm m diameter and 1 75 mm m depth for spinal fluid 
Syr-nge. Luer type 1 or 2 ml 
/DRL antigen emuision ootties 30 ml round, glass-stoppered narrow 
mouth, approximately 35 mm in diameter with flat inner bottom 
surface 
Serological pipet'es 5 0 ml I 0 ml and 0 2 ml 
Walei bath 56 C 
Light microscope with 'OX ocular and 10X obiective 
Distii'ed water 
0 9° i saline solution 
tO 1 saline solution 
Absolute alcohol ana acetone 
interval timer 
pH meter 
Preparation of Specific Glassware 
Syringes with needles and emulsion bottles Wash by hand in the 
'oilowmg manner 
1 Pre-nose with *ap water 
2 Soak and wash thoroughly m a glassware detergent solution 
3 Rmse with tap water 6 8 times 
4 Rinse with unusea distilled or demineralized water 
5 Rmse with absolute alcohol 
6 Rmse with acetone 
7 Air -dry until acetone odor :s completely eliminated 
9 Remove needles from syringes for storage 
Ceramic ringed slides 
1 Pre-r.nse witn tap wa'er 
2 Wash with a glassware detergent solution 
3 Rmse with 'ap water 3 4 times 
4 Rmse with unused distilled or demineralized water 
5 Wipe dry with clean lint free coth If cleaned slides do not allow 
serum to spread evenly within inner surface of circle, ireat the slides 
as follows 
6 Scrub the slides with a non-scratching cleanser 
7 Ory and poi;sn wi'h a clean imt-free cloth 
NOTE Avoid prolonged soaking ot ceramic-ringed slides m detergent 
solution since tne ceramic rings will become brittle and flake ott 
Preparation of VDRL Antigen Emulsion 
t Pipette 0 4 mi of VDRL buffered saline directly to the bottom of a 
VDRL antigen emulsion Dottle 
2 Gently tilt bottle so that VDRL Outfered saline will cover entire inner 
surface of bottom 
3 F'om the 'ower half of a 1 0 ml pipette graduated to the tip. add 
0 5 ml of VDRL antigen as follows 
a Keep the pipette m the upper 1/3 area of the bottle Do not let it 
touch the saime 
b While rotating the bottle around a circle approximately 2" m 
diameter allow the antigen to be added dropwise to the VDRL 
buttered saime. 
c Allow approximately 6 seconds to add antigen, then blow out 
remaining antigen from oipette 
4 Continue rotation of bottle for 10 seconds 
5. Add 4 i ml of VDRL buffered saline to bottle, allowing ihe VDRL 
buttered saline to flow down the side of the bottle 

6 P'ace ;ne giass stooper n 'he ocnie ana snake ne oot-e *'cn 
bottom to ico ana oacn aooroximatety JO times m '0 seconds 
7 Let VORL antigen emulsion stand witnout furtner disturoance 3' 
10 mmutes 
3 VORL antigen emulsion is ready to use Swirl gently prior to using 
Antigen emulsion may De usea aunng one Jay 
NOTE Check pH of VORL buffered saline prior to preparing VORL 
antigen emulsion VORL Dufferea saline outside the range of 
pH 6 0 * 0 1 snouia be discarded. 
Allow VORL antigen ana VORL Dufferea saline to reach 23 ■ 29 C before 
preparing VORL antigen emulsion 
Use only emulsion Dottles with flat inner bottom surfaces that allow the 
mitiai VORL Dufferea saline to evenly cover tne inner bottom surface of 
'he Dottle if the VORL Dufferea saline Deaas or does not spread evenly 
to cover tne Dottom of Dottle, rewash bottle 
Eor reproducible results the VORL antigen emulsion must De checked 
daily for proper reactivity by testing with 3acto VORL Test Control 
Serum Set Only those VORL emulsions producing tne established reac- 
'ivity pattern of the control serum should be used 
NOTE Mix VORL emulsion prior to using m test by gentle swirling of 
emulsion bottle Oo not mix emulsion by forcing back and forth through 
the syringe and needle 
VDRL SLIDE QUANTITATIVE TEST ON SERUM 
1 Prepare a two-fold serial dilution of inactivated serum in 0 9% sanne 
as follows (12. 1 4. 1.8. 116 t 32) 
2. Test each serum dilution using Qualitative Test Procedure 
3 Report results m terms of the greatest serum dilution that produces 
a Reactive [not Weakly Reactive) result in accordance with the 
following examples: 
or 8 diiutic 
Reactive 
W w 
N(rough) W 
W N 
If Reactive results are obtained through dilution 1:32. preoare further 
two-fold serial dilutions in 0 9% saline <1 64 i 128 and 1.256) and retest 
using Qualitative Test Procedure 
Calibration of (Delivery Needles without Bevels 
1. With 18 gauge needle attached to i ■ 2 ml Luer-type syringe till 
syringe with antigen emulsion. 
2. Hold the syringe with needle in a vertical position and expel 'he 
emulsion dropwise into the emulsion bottle. 
3. Count the number of drops delivered per ml of emulsion The needle 
should deliver 60 drops ± 2 drops per ml of antigen emulsion 
4 Ad|ust drops per ml by either narrowing the open end of the needle 
to allow more drops per ml to be delivered or opening the end of the 
needle to allow fewer drops per ml to be formed 
Standardization of VDRL Antigen Emulsion 
1 Rehydrate each control serum with 3 mi distilled water and rotate in 
an end-over-end motion to dissolve completely 
2 Inactivate serum dilutions at 56 C for 30 minutes 
3 Cool to room temperature 
4 Perform qualitative VDRL Slide Test on all serum dilutions with 
VDRL antigen emulsion Test serum dilutions within 1 hour alter 
inactivation 
5 Read test immediately as follows. 
Reactive Serum Medium or large clumps 
Weakly Reactive Serum Small clumps 
Nonreactive Serum No clumping with complete 
dispersion of emulsion particles 
Select a VDRL antigen emulsion which produces the specified reactivity 
pattern with each control serum 
Perform the VDRL Slide Test procedures within the temperature range 
23 29 C since lower temperatures decrease test reactivity and higher 
temperatures increase test reactivity 
VDRL SLIDE QUALITATIVE TEST ON SERUM 
1 With 1 0 ml pipette, mix inactivated serum several times, then using 
same pipette add 0 05 ml of serum into 1 ring of the paraffin-ringed 
or ceramic ringed glass slide Do not use glass slides with 
concavities, wells, or glass rings for the VORL Qualitative or 
Quantitative Test Procedures on serum Do not use glass slides with 
ceramic rings that have begun to flake off or that permit spillage of 
the antigen serum mixture when slides are rotated at the prescribed 
speed 
2 Spread the serum with a circular motion of the pipette tip so that the 
serum covers the entire inner surface of the paraffin or ceramic ring 
Use only clean slides that allow serum to evenly cover entire surface 
within ceramic or paraffin ring. 
3. While holding the syringe with an 18 gauge needle in a vertical posi¬ 
tion. carefully add 1 drop of antigen (1/60 ml) to the serum. Do not 
allow needle to touch the serum 
4 Place the paraffin- or ceramic-ringed slides containing the serum 
and antigen on a rotator and rotate for 4 minutes at 180 rpm 
circumscribing a JV diameter circle 
5 Prevent evaporation of slides during rotation m a dry climate by 
covering slides with a moisture chamber (box lid containing a 
moistened blotter) 
6 Observe ringed slides microscopically with a 10X ocular and a 10X 
obiective immediately after rotation 
7 Read test as follows 
Medium and large clumps R Reactive 
Small clumps W Weakly Reactive 
No clumping or very slight roughness N Non-Reactive 
NOTE. Quantitatively retest each serum producing Weakly Reactive or 
rough Non Reactive results when tested qualitatively since prozone 
reactions are encountered occasionally 
VDRL SLIDE TESTS ON SPINAL FLUID 
VORL antigen and VDRL buttered saline may be used for spinal fluid 
testing m accordance with the VDRL Slide Tests on spinal fluids as 
stated on pages 40. 41 and 42 in the Manual of Tests for Syphilis 1969 - 
LIMITATIONS OF THE PROCEDURE 
VDRL antigen slide tests are non-specific tests tor syphilis All sera and 
spinal fluids expressing a Reactive or Weakly Reactive VDRL test m 
me absence of clinical evidence of syphilis should be subiected to other 
syphilis serology tests such as FTA-ABSJ J or HATTS. 
Reactive or Weakly Reactive VDRL test results should not be con¬ 
sidered as conclusive evidence that the patient is syphilitic Conversely 
a Non-reactive VDRL test by itself does not rule out the diagnosis of 
syphilis 
SPECIFIC PERFORMANCE CHARACTERISTICS 
In various stages of untreated syphilis, the likelihood of obtaining a 
Reactive VDRL is as follows: 
Stag® of 
Untreated Syphilis 
Primary 
Secondary 
Early Latent 
Late Latent 
Late (Tertiary) 
> Reactive 
76 
100 
95 
72 
70 
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PACKAGING 
Bacto VDRL Antigen with 0388-56-5 5 ml 
8acto VDRL Buffered Saline 0388-49-5 10 x 0 5 ml 
Bacto VDRL Test 
Control Serum Set 3520-32-7* 1 set 
’Store at 2 ■ 8 C 
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Appendix 4 78 
FLUORESCENT TREPONEMAL ANTIBODY 
ABSORBED (FTA-ABS) TEST REAGENTS 
Bacto FTA Antigen 
Bacto FTA Serum Reactive 
8acto - FTA Sorbent Control 
Bacto - FTA Sorbent 
Bacto - FA Human Globulin Antiglobulin (Rabbit) 
Bacto - FA Mounting Fluid 
Bacto - FA Buffer Dried 
Tween 80® 
The fluorescent treponem antibody absorbed test performed with the 
above listed reagents is an indirect FA procedure for detecting human anti¬ 
body against Treponema pallidum, the causative agent of syphilis. Since 
its introduction in 1957 by Deacon, Falcone and Harris1, the FTA Test 
has increased in popularity. However, certain difficulties with respect to 
sensitivity versus specificity have been encountered. 
In its original form the test utilized a 1:5 dilution of patient's serum At 
this dilution, a large number of false positive reactions were encountered. 
There seemed to be a cross reaction of the treponemal antigen with 
antibodies to group antigens which are common to all treponemes. The 
titer of serums containing the non-specific group antibodies ranged from 
1:5 - 1:100. 
In 1960 Deacon, Freeman and Harris2 introduced a modification of the 
FTA Test. This procedure was called the FTA-200 Test and utilized a 
1 200 dilution of patient's serum By increasing the dilution of the serum, 
the non-specific antibodies were diluted beyond their titer and could no 
longer interfere with the test. However, by testing a high dilution of serum, 
the sensitivity of the test is decreased in that the low titered primary cases 
of syphilis are not detected. This has been substantiated by Eng, Nielsen, 
Wercide and Wilkinson5-4 
It has been the trend since the introduction of the FTA-200 Test to return 
to the 1:5 dilution and eliminate the non-specific antibodies in the serum. 3. 
Deacon and Hunter5 demonstrated that by using appropriate absorption 
procedures the reactivity of non-specific antibodies can be eliminated or 
blocked. This absorptive procedure has developed into an improved test, 
the FTA-ABS Test* 
Treponemal Antigen Tests such as the FTA-ABS Test are used primarily 
as confirmatory tests in diagnostic problem cases; e.g. patients in which 
the clinical, historical or epidemiological evidence of syphilis is equivocal. 
The FTA-ABS Test is more sensitive than the VDRL in Primary Syphilis 
and Late Latent and Tertiary Syphilis. 
The persistant reactivity of the FTA-ABS Test to a treated case of syphilis, 
sometimes for life, minimizes its use for following the response to therapy 
as well as making it unreliable for detecting new untreated cases in 
epidemiologic investigations. 
REAGENTS 
Bacto - FTA Antigen is a desiccated, standardized killed suspension of the 
Nichols strains of T pallidum. Unreconstituted antigen is stored at 2-8 C 
To rehydrate, add 1 ml sterile distilled water per vial and rotate to effect 
complete solution The antigen suspension should be thoroughly maxed 
with a disposable pipette and rubber bulb. Drawing the suspension into and 
expelling from the pipette 8 10 times, will break the treponema! clumps 
and insure an even distribution of treponemes. 
Treponemal antigen smears may be prepared in the following manner 
1. On clean grease free slides inscribe 2 circles 1 cm in diameter with a 
diamond point stylus. Remove any free glass particles by wiping slides 
with a piece of clean gauze. 
2. Within the inscribed circles, smear 1 loopful of Bacto - FTA Antigen 
using a standard 2 mm. 26 gauge, platinum wire loop. Allow to dry at 
least 15 minutes at room temperature. 
3. Immerse the dry slides into acetone for 10 minutes. This fixes the 
treponemes to the slide so they will not wash off during the rinsing 
procedures later in the test. Not more than 50 slides should be fixed 
with 200 ml of acetone. 
4. It is recommended that a freshly rehydrated bottle of Bacto - FTA 
Antigen be used in its entirety for making Treponema! antigen smears 
on the same day. These slides may then be stored at -20 C or lower 
after acetone fixation. The frozen slides are usable as long as satisfactory 
results are obtained with the controls. Thawed slides should not be 
refrozen. 
Bacto - FTA Serum Reactive is a standardized, desiccated human serum for 
use as a positive control m the FTA-ABS Test. To rehydrate this serum, add 
5 ml or 1 ml good quality distilled water as indicated by the package size. 
When diluted 1:5 in FA buffer or sorbent a 4+ fluorescence will be 
obtained. To obtain a 1+ fluorescence this serum must be diluted further 
in Bacto - FA Buffer. This dilution will vary with each lot and is provided 
in the instructions received with each vial. The undiluted serum may be 
dispensed m 0.4 ml aliquots and frozen until needed. Do not refreeze 
thawed aliquots. This serum should be heated at 56 C for 30 minutes 
before using. 
Bacto FTA Sorbent is a standardized extract of the non-pathogenic 
Reiters treponeme containing group Treponemal antigens. It is designed 
to be used m tne FTA-ABS Test for blocking the action of non-specific 
antibodies in the serum. The sorbent comes ready to use and is supplied 
in vials of 5 ml and boxes of 6 x 5 ml. It is recommended that Bacto 
FTA Sorbent be stored either at 2 - 8 C or in the frozen state at -20 C 
after it is received in the laboratory A 1:5 dilution of the serum is made 
by placing 0 05 ml of heated serum into 0 2 ml sorbent and mixing 
thoroughly. 
Bacto - FTA Sorbent Control is a desiccated standardized human serum 
demonstrating at least a 2+ fluorescence m the FTA-ABS Test at a 
dilution m Bacto FA Buffer of 1 5. At a dilution of 1 5 in Bacto - FTA 
Sorbent no reactivity will be observed. This serum is supplied in 6 x 0.5 ml 
vials and is good for 1 week after rehydration if refrigerated at 2-8 C or 
longer if stored in the frozen state 
Tween 80® 
A 2% solution of Tween 80 may be prepared as follows 
Heat the bottle of Tween 80 and 98 ml Bacto - FA Buffer in a 56 C 
water bath until both solutions are at 56 C. 
Using a 2 ml pipette graduated to the tip, add 2 ml Tween 80 to the 
Bacto - FA Buffer and rinse the pipette thoroughly. 
The 2% solution should have a pH of 7 0 - 7.2. The solution keeps 
well in the refrigerator at 2 - 8 C, but should be discarded if the pH 
changes or if a precipitate is noticed. 
Bacto - FA Human Globulin Antiglobulin (Rabbit) is a fluorescein conju¬ 
gated anti-human globulin designed for use in the FTA-ABS Test. It is 
used as an indicator system to detect the presence of human syphilitic 
antibodies on the treponemal antigen. It is a desiccated product and is 
supplied in 5 ml and 1 ml quantities. In rehydration, use the amount of 
good quality distilled water indicated by the package size. The rehydrated 
conjugate may be stored in the refrigerator at 2 8 C or in 0 4 ml aliquots 
at 20 to -40 C. 
Each vial is supplied with a dilution titer. This titer has been confirmed in 
several laboratories. With each new lot of conjugate used, the titer should 
be confirmed with the fluorescent assembly in use at the time This may 
be done in the following manner 
1 Prepare serial dilutions of the conjugate with the 2% Tween 80 
solution. The serial dilutions should include the titer specified on the 
vial. 
2. Each conjugate dilution is tested with the Bacto - FTA Serum Reactive 
diluted 1:5 m Bacto - FA Buffer and a non-specific staining control 
(conjugate + antigen). 
3. A known conjugate is set up with the Bacto - FTA Serum Reactive (4+) 
a minimally reactive (1+) serum, and a non-specific staining control tc 
control reagents and test conditions. 
4. The dilution to be used in the test is taken as 1 doubling dilution 
lower than the 4+ end point (the highest dilution of conjugate givmc 
a 4+ fluorescence with the 4+ control serum'. 
For In Vitro Diagnostic Use. 
PREPARATION of the SPECIMEN 
Test and control serums should be heated at 56 C for 30 minutes before 
being tested Previously heated serum should be reheated for 10 minute 
on the day of testing. 
PROCEDURE 
Procedure steps are taken essentially from Pub. Hlth. Serv , Pub. No 
411, 1969s 
Code 2344 
Code 2439 
Code 3266 
Code 3259 
Code 2449 
Code 2329 
Code 2314 
Code 3118 
1. 
2 

Materials provided 
Bacto FTA Antigen 
Bacto - FTA Serum Reactive 
Bacto - FTA Sorbent Control 
Bacto - FTA Sorbent 
Tween 80 
Bacto FA Human Globulin Antiglobulin (Rabbit) 
Bacto ■ FA Mounting Fluid 
8acto • FA Buffer. Oried 
Materials required but not orovided: 
Diamond point s'v'us (not needed if pre-etched slides are used) 
Plain slides or 1 < 3 inch frosted end approximately 1 mm thick 
or slides with circles already inscribed 
Cover slips. No 1 22 mm square 
2 mm. 26 gauge, platinum wire loop 
Acetone 
Distilled water 
Water bath ar 56 C 
Interval 
Staming csn /nth removable slide carriers 
Moisture chamber 
0.2 ml serological pipette 
5 mi se^oiogical pipette 
1 mi jr-.plogical oipette 
3.oulous oaoer 
Applicator sticks 
Fluorescent microscope assembly 
1 Identify previously prepared slides to correspond to the serums and 
control serums to be tested. 
2 3erore using, slides taken from the freezer must be completely thawed 
and thoroughly dry. 
3. Prepare r~e proper dilutions for the 4+ control, the 1+ control, the 
non-specific serum controls and for the unknown serums to be tested 
The 1 5 dilutions may be prepared by adding 0.05 ml serum (using a 
0 2 ml pipette graduated to the tip and measuring from the bottom) 
to 0 2 ml soroent or Bacto FA Buffer, whichever is required. Mix 
the dilution no less than 8 times. All unknown serums are diluted in 
FTA Sorbent only 
4 Do not dilute the control and unknown serums more than 30 minutes 
before they are to be placed on the antigen smears. 
Controls 
a Reactive 4-*- Control 
Bacto FTA Serum Reactive diluted 15 in Bacto - FA Buffer and 
m Bacto FTA Sorbent A 4+ fluorescence should be observed 
with both dilutions, 
b Minimally Reactive (1+) Control 
A dilution of Bacto - FTA Serum Reactive togive a 1+fluorescence. 
This control is used as a reading standard to indicate the minimal 
degree of fluorescence that can be reported as reactive, 
c. Non-Soecific Serum Control 
1 Antigen smear treated with 0 03 ml of Bacto - FA Buffer. 
2 A*v2en smear treated with 0.03 ml of Bacto - FTA Sorbent. 
Test runs n which the proper control results were not obtained are 
consider-?.’ unsatisfactory and should not be reported. 
5. Cover e v oentified antigen smear with the corresponding serum 
dilution j-'c me oroper non-specific staining controls with Bacto - FA 
Buffer or 8ac:o FTA Sorbent. Make certain the entire smear is 
covereo The snaft of an applicator stick held parallel to the surface of 
the smear is an effective tool for this purpose. 
6. Place the into a moist chamber to prevent evaporation and incu¬ 
bate at 35 - 37 C for 30 minutes. 
7 Place the slides .n a slide carrier and rinse them in running Bacto - FA 
Buffer for 5 seconds and then soak in Bacto - FA Buffer for 5 minutes. 
Agitate the slides by dipping them in and out of the buffer 10 times. 
Repeat the soaking and agitation process for another 5 minutes in 
fresh Bac*o FA Buffer. 
8. Rmse the slides m jnmng distilled water for 5 seconds and blot dry 
with bibulous oaper 
9 Dilute the con,ugate to its working titer using FA Buffer containing 
2% Tween 80 
10 Cover each smear with approximately 0 03 ml diluted coniugate Make 
certain the entire smear is covered. 
11 Repeat steps 6, 7 and 8 
12 Mount slides immediately using a small drop of Bacto - FA Mounting 
Fluid and a cover slip. Be careful not to entrap air bubbles in the 
mounting fluid between the slide and cover slip. 
12 Examine slides microscopically as soon as possible using mercury arc 
illumination and a high power dry objective A combination of BG 12 
exciting filter, not greater than 3 mm thickness and OG 1 barrier 
filters or their equivalents has been found to be satisfactory. Slides may 
be stored in a darkened room and read within 4 hours. 
14 Non-reactive smears should be checked using illumination from a 
tungsten light source in order to verify the presence of treponemes. 
RESULTS 
Using the 1+ control serum as a reading standard, record the intensity of 
fluorescence and report as follows: 
READING 
2+ - 4+ 
1 + 
less than 1 + 
INTENSITY OF FLUORESCENCE 
Moderate to strong 
Equivalent to 1+ control 
Weak but definite 
None or vaguely visible 
REPORT 
Reactive 
Reactive 
Borderline 
Non-reactive 
Retest all specimens with a fluorescence of 1+ or less. When a specimen 
initially read as 1+ gives a 1+ or better fluorescence, it is reported as 
reactive All other results are reported as borderline It is not necessary 
to retest non-reactive specimens. 
LIMITATIONS of the PROCEDURE 
There is a degree of difficulty in determining whether a reading is weak or 
vaguely visible The ability to make this distinction is critical since a non- 
reactive (vaguely visible to none) serum is not retested. 
The test cannot be used to follow the response to therapy nor can it be 
relied upon to detect new, untreated cases in epidemiological investigations. 
SPECIFIC PERFORMANCE CHARACTERISTICS 
In various stages of untreated syphilis the likelihood of obtaining a reactive 
FTA-ABS is as follows;1 
STAGE Of UNTREATED SYPHILIS % REACTIVE 
Primary 86 
Secondary 100 
Early latent 99 
Late latent 96 
Late (Tertiary) 97 
REFERENCES 
1 Proc Soc Exp. Biol and Med.. 96.477,1957 
: ibid . 103 827.1960 
1 wid. Hlth Org. Document WHO/VOT 314 WHO/VDT/RES/29. Mar 1963 
4 Proc Royal Soc Med , 56 478.1963 
Proc. Soc Exp. Biol, and Med . 110 352.1962 
* Publ Hlth. RPTS.. 79 410.1964 
' Publ Hlth Service Publ No 1660, 1968 
4 Publ Hlth. Sorvice Publ No 41 1. 1969 
PACKAGING 
Bacto - FTA Antigen 2344-50-0* 1 ml 
Bacto - FTA Serum Reactive 2439-50-6* 1 ml 
2439-56-0* 5 ml 
Bacto - FTA Sorbent 3259-56-5* 5 ml 
3259-57-4* 6 x 5 ml 
Bacto - FTA Sorbent Control 3266-49-6* 6 x 0.5 ml 
Bacto - FA Human Globulin 2449-50-4* 1 ml 
Antiglobulm (Rabbit) 2449-56-8* 5 ml 
Bacto - FA Mounting Fluid 2329-57-2* 6 x 5 ml 
Bacto - FA Buffer, Dried 2314-33-8 6 x lOg 
2314-15-0 100 g 
Tween 80® 3118-15-6* 100 g 
* Store 2 8 C. 
© Atlas Chemical Co 
DIFCO LABORATORIES 
1333 DETROIT MICHIGAN USA August 1974 
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TPHA TEST KIT SIS S 
A HEMAGGLUTINATION TEST FOR SYPHILIS 
USING ERYTHROCYTES SENSITIZED WITH PATHOGENIC 
TREPONEMA PALLIDUM EXTRACTS 
MICRO HEMAGGLUTINATION ASSAY TECHNIQUE 
FD101 Qualitative 100 tests or Quantitative 30 tests 
FD102 Qualitative 50 tests x 2 or Quantitative 1 5 tests x 2 
FD106 Qualitative 25 tests x 4 or Quantitative 7 tests x 4 
FD103 Qualitative 250 tests x 2 or Quantitative 75 tests x 2 
CHARACTERISTICS: 
TPHA (Treponema pallidum hemagglutination) test kit is prepared using a compo 
nent of Treponema pallidum which has been adsorbed onto fixed sheep red blood 
cells. In the presence of antibodies to T. pallidum, the causative agent of syphilis, 
the sensitized red blood cells will be hemagglutinated. making possible a simple, 
easily performed and readable test. A special absorption diluent is included in the 
kit to eliminate false positive reactions, therefore this TPHA test has a high degree 
of specificity and eliminates a high percentage of the Biological False Positives 
(BFPs). 
REAGENTS 
A. Reconstituting Solution 
This consists of distilled water. 
B Absorbing Diluent 
This liquid consists of sonicated cell 
membranes from sheep and ox erythro¬ 
cytes. normal rabbit testicular extract, 
sonicated Reiter treponemes. normal rab¬ 
bit serum. Tween 80 and acacia powder 
in phosphate buffered saline (PBS), 
pH 7.2. This reagent is used to preabsorb 
and dilute sera, and to prepare the work¬ 
ing dilutions of the Sensitized and I'n 
sensitized Cells. 
C. Sensitized Cells (Lyophilized) 
a. The rehvdrated antigen is a 2.5% sus¬ 
pension of formalinized, tanned sheep 
erythrocytes which have been sensi¬ 
tized with sonicated T\ pallidum. 
b Prepare a working dilution of antigen 
b\ adding: one part of the rehvdrated 
suspension to i i parts .»f \bsorhinn 
D.iutm Uu.j dilution;. 
D Unsensitized Cells (Lyophilized) 
When rehydrated, this is a 2.5% suspen¬ 
sion of formalinized, tanned sheep ery¬ 
throcytes (not sensitized with T. palli¬ 
dum antigen). A working dilution of 
1:6.5 is prepared, allowing 0.075 m2 for 
each test serum. 
E Reactive Control (Lyophilized) 
Reconstitute with 1 m2 of Reconstituting 
Solution. Upon reconstitution, this Con¬ 
trol is PREDILUTED TO 1 80. Titer of 
this Control is 1:2560 plus or minus one 
doubling dilution. 
FD101 
1 x 10 m9 
2 \ 28 mC 
FD 102 
1 \ 10 mC 
2 v 28 m2 
FD106 
1 x 10 mC 
2 x 28 mC 
FDIO'J 
1 x 28 mC 
2 x 170mC 
1 x 2.5 m2 2x1 3mC 4x0.8 m2 2x7 5 mV 
1 x 1 UmV I x I OmC IxIOmt 2 \ l.0m£ 
EQUIPMENT NECESSARY FOR PERFORMING ASSAY 
1. Microdiluters (0.025 m2) 
2. Calibrated pipet droppers 0.025 mC/drop (included in kit) 
3 Go no-go delivery testers (blotters) 
4. Rigid or permanent type U-shaped microplate. Make sure that the wells of the 
plate are free from dust or lint before dropping reagents. 
PRECAUTIONS 
1. Lyophilized and reconstituted reagents should be stored at 2~-10°C and dis¬ 
carded if they become contaminated or do not demonstrate the proper reactivity 
with the Controls. 
2. The reagents must be reconstituted with Reconstituting Solution and mixed 
thoroughly to ensure a homogenous suspension. We would suggest that the 
rehydrated reagents be LEFT AT ROOM TEMPERATURE FOR AT LEAST 50 
MINUTES BEFORE USE. 
3 Reconstituted reagents should be stored at 2-l0°C and used within 5 days. 
Working dilutions of Sensitized and Unsensitized Cells should be stored at 
2 1 0°C and used within one day. 
4 Each batch of reagents has been standardized to produce the proper reaction, 
therefore, reagents should not be interchanged with those of other batches. 
5. The product or their residues must not be allowed to come into contact with 
ruminating animals or swine. 
SHELF LIFE 
18 months from production date (refer to outer package for expiry date) 
CONTROLS 
1. Test Serum Control 
The 1:20 dilution of the test serum is tested using 0.075 m2 of the working 
dilution of the Unsensitized Cells (Well 3). No hemagglutination should occur. 
2. Reagent Controls 
The Absorbing Diluent is tested using both the Sensitized and the Unsensitized 
Cells as shown in Table 3. There should be no reaction. 
3. Reactive Control 
When rehydrated, this is a 1 80 dilution of Reactive Control Serum and is ready 
for use. Titer of this Control is 1 2560 and the result may vary plus or minus 
one doubling dilution. 
PREPARATION OF MICRODILUTING EQUIPMENT 
1. Microdiluter Preparation 
a. Rotate microdiluters in distilled water to clean. 
b Flame microdiluters over a Bunsen burner and then quench in cold water 
2. Go No-go Delivery Test (delivery test and prewetting are accomplished in the 
same operation). 
a. Fill each microdiluter by touching it to the surface of PBS or saline solution. 
Do not wet the canopy (top) of the loop. 
b. Touch the microdiluter to the center of one of the circles on the Go No-go 
delivery tester (blotter), and observe the dampened area within the circle. 
c. A properly prepared microdiluter will deliver all contained fluid which will 
be sufficient to immediately dampen the entire area within the circle. 
3. The calibrated ptpet dropper must be clean. To assure proper delivery of fluid, 
wipe the exterior of the dropper tube after filling and hold the dropper in a ver¬ 
tical position when adding fluid to the tray cups. 
CLEANING PROCEDURE 
Sufficient care should be taken in cleaning the equipment since this process has 
a great influence on the reaction 
.Microplates, pipets, droppers and diluters should be rinsed in running water and 
then soaked in a neutral compound detergent solution for 4 or 5 hours. Rinse again 
in running water, then rinse in purified water and dry in incubator (37°C) or in the 
open air 
QUALITATIVE ASSAY ON SERUM 
1. Using a calibrated pipet dropper (0.025 m2), place Absorbing Diluent in the wells 
as shown in Table 1. 
(Note: 5 wells will be used for each test serum.) 
2. Place 0.025 m2 of test serum into Well 1. Using microdiluter?, mix the contents 
of Well 1. Remove the diluters and place into Well 2. Rotate iO mix and move 
the diluters to Well 4 (omit Well 3). Mix again and move diluters to Well 5. Mix 
and discard the tluid in the diluters. Place clean diluters (Refer to Cleaning Pro- 
redure) into Well 2 Rotate to mix and transfer diluters to Well 3. Rotate again 
and then distald icnijin.iig 1 luui in lhe diluters. (Refer to 1 able 1.) 
3 After completing the dilutions in each tray, cover and incubate at room tern- 
pert ure (15—25°C) for at least 30 minutes. 
4. Using one of the pipet droppers (enclosed in kit), add 0.075 m2 (3 drops) of 
Unsensitized Cells to Well 3. 
5. Using the other pipet dropper, add 0.075 m2 (3 drops) of Sensitized Cells to 
Wells 4 and 5. 
6 Reactive Control (Refer to Table 3.) 
Drop 0.025 m2 Absorbing Diluent into the wells of a microplate as shown in 
Table 3. Place 0.025 m2 of Reactive Control Serum (PREDILUTED TO 1 :80) 
in Well 1. Make a serial dilution in Wells 1 through 5. Add 0.075 m2 Sensitized 
Cells to Wells 1 through 5. 
7. Reagent Controls (Refer to Table 3.) 
Place 0.025 m2 Absorbing Diluent in Well 7, add 0.075 m2 Sensitized Cells. 
Place 0.025 m2 Absorbing Diluent in Well 8. add 0.075 m2 Unsensitized Cells. 
8. Shake the trays gently, cover with an empty tray. 
9. Incubate the trays at room temperature (15 —25°C) for at least 2 hours. The 
incubation period may be extended overnight wirh no change in parrerns. 
10 Read the settling patterns of the red blood cells using a tray viewer to 
visualize the patterns 
11. Readings are scored on a scale of (-) to (4+) and the degree of hemagglutination 
is judged accoiding to the following criteria: 
Degree of Hemagglutination Reading Interpretation 
Smooth mat of cells covering entire bottom of well, 
edges sometimes folded 
4+ Reactive 
Smooth mat of cells covering less area of well 3+ Reactive 
Smooth mat of cells surrounded by red circle 2 + Reactive 
Smooth mat of cells surrounded by smaller red circle 1 + Reactive 
Button of cells having small “hole” in center + *** Retest 
Definite compact button in center of well or may 
have a very small “hole" in the center - 
Nonreactive 
12. The results of the Controls should conform to the criteria outlined in the CON 
TROLS section. 
13. Interpretation 
a. Report as REACTIVE a serum showing hemagglutination of (1+) or highei 
with Sensitized Cells, provided there is no hemagglutination with the Un 
sensitized Cells. 
b Report as NONREACTIVE a serum showing no hemagglutination (—) with 
Sensitized Cells and Unsensitized Cells. 
***c. Reading of (±) may occur because of several technical factors. Therefore it is 
suggested that specimens giving (±) readings be retested. If repeat (±)reading 
are shown, rake another serum sample (after several days) and rhen perform the 
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qualitative test again, or test the serum bv a different method (FTA-ABS. etc) 
14. If non-specific hemagglutination occurs with the I'nsensitized Cells, absorption 
with HA Absorbent and retesting is recommended (HA Absorbent available 
separately). 
QUANTITATIVE ASSAY ON SERUM (Refer to Table 2.) 
If serum endpoints titers are desired, quantitatively test all sera that show a 
RF. ACTIVE result in the Qualitative Assay. 
I. As shown in Table 2, place the Absorbing Diluent in each well required for 
dilutions. 
2 Place 0.025 mC of test serum in Well 1. perform serial dilutions with diluters. 
Rotate diluters in Well I and move to Well 2. Rotate and move to Well 4 (omit 
Well 3). Continue rotating and transfering diluters from one well to the next and 
discard the excess from the last well. Place clean diluters in Well 2, rotate to mix 
and move to Well 3. Mix well and discard the excess. The final serum dilution 
in Wells 3 and 4 is 1:80. 
3 After completing the dilutions in each tray, incubate at room temperature (15- 
25°C) for at least 30 minutes. 
4. Add 0.075 mC Unsensitized Cells to Well 3. 
5. Add 0.075 mC Sensitized Cells to each of Wells 4 to the final well. 
6. Set up Reagent Controls (see Step 7 in "QUALITATIV E ASSAY ON SERUM ). 
7. Complete tests and read as described in the Qualitative Assay (see Steps 8 
through 12 in "QUALITATIVE ASSAY ON SERUM”). 
8. Quantitative tests showing NONREACTIVE results in the Control are reported 
in terms of the highest dilution gi ving a REACTIVE result (1 +. 2 + . 3-< or 4+) 
illustrated b elow: 
Final Serurr i Dilution 
1:80 1 .160 1 : ; 320 1 .640 I : 1280 1:2560 Report 
4 + 4+ 3 + 1 + ± R 1 640 
3 + 2 + 1 + - R 1:320 
1 - _ _ - - R 1:80 
± - - 
*1 detest 
2 + 4+ 4+ 4-*- 2+ ± R 1: 1280 
*lt is suggested that specimens giving (±) reading at 1.80 be retested. Repeat (±) 
readings are reported as NONREACT1V E. 
9. If non-specific hemagglutination occurs with Unsensitized Cells (Test Serum 
Control), retest using one of the two methods below: 
\ \bsorh the non-specific factors with H A \bsorbent and retest I FI A Absorbent 
is avartabte^rparatetv? — 
B Prepare dilutions in two rows of wells as shown in Table 2. 
f 1 | Add 0.075 mC of Sensitized Cells to each well of one row. 
(2 | Add 0.075 mK of I'nsensitized Cells to the other row. 
10. Report as REACTIVE without reference to titer, if: 
(1 ] The hemagglutination with Sensitized Cells is at least two doubling dilutions 
greater than with L’nsensitized Cells: 
(2 | The first dilution showing hemagglutination with Unsensitized Cells has a 
(3-*-) or (4+) reaction with Sensitized Cells. 
11 Report as "Inconclusive. Non-specific Hemagglutination in Serum Control", if: 
[1| The hemagglutination with Sensitized Cells is only one doubling dilution 
greater than with L'nsensitized Cells; 
(21 The hemagglutination with Sensitized Cells is at the same dilution as the 
Sensitized Cells. 
Table 1 Outline of Qualitative Test 
Cup Test 
No. Serum + 
ml 
Absorbing 
Diluent 
ml 
Serum 
" Dilution 
Diluted 
Unsensitized 
Cells, ml 
Diluted 
Sensitized 
Cells, ml 
Final 
Serum 
Dilution 
1 ,0.025 0.025 1 :2 
2 '0.025 0 1 1:10 
3 (0.025' 0.025 1 20 0.075 1 80 
4 '0.025 0.025 1:20 0.075 1:80 
5 '0.025 0.025 1 :40 0.075 1 : 1 60 
Table 2 Outline of Quantitative Test 
Cup 
No. 
Test 
Serum + 
ml 
Absorbing 
Serum 
Diluent =..... ( Dilution 
Diluted 
Unsensitized 
Cells, ml 
Diluted 
Sensit ized 
Cells, ml 
F inal 
Serum 
Dilution 
1 0.025 0.025 1 2 
2 '0.025\ 0.1 1 10 
3 'o.ozy 0.025 1 20 0.075 1 :80 
4 '0.025 0.025 1 20 0.075 1 :80 
5 v0.025 0.025 1 40 0.075 1:160 
6 '0.025 0.025 1 80 0.075 1:320 
7 ‘0.025 0.025 1 160 0.075 1 640 
8 '0.025 0.025 1 320 0.075 1:1280 
9 '0.025 0.025 1 640 0.075 1:2560 
10 '0.025 0.025 1 1 280 0 075 1:5120 
Table 3 Controls 
Cup Absorbing Control Diluted Diluted Final 
No Diluent Seruru U>.sensitized Sensiliztu Serum 
ml Dilution Cells, ml Cells, ml Dilution 
Reai t ive 
Control 
Serum.ml 
1 0.025 (180) 0.025 1 1 60 o
 
o
 
1:640 
2 0 025( 1 160) 0.025 1:320 0.075 1:1280 
3 0.025(1:320) 0.025 1 640 0.075 1 2560 
4 0 025(I 640) 0.025 1 1280 0.075 1:5120 
5 0.025( 1 . 1 280) 0.025 12560 0.075 1 10240 
Reagent Co ntrols 
1 0.025 - - 0.075 - 
2 0.025 0.075 
- 
REFERENCES 
1 Rathlev T. 1 965 Hemagglutination Tests Utilizing Antigens from Pathogenic 
and \pathogenic Treponema pallidum. WHO Document VDT/RES/77.65 
2. Fomizawa, T. and Kasamatsu, S. 1966 Hemagglutination Tests for Diagnosis 
of Syphilis. A preliminary Report. JAP. 1 MED. SCI. BIOL. 1 9: 305-308 
3. Tringali. G. 1970. Hemagglutination Test Utilizing Pathogenic Treponema 
pallidum (TPHA) in Comparison with other Serologic Tests for Syphilis 
ANN A LI SCLAVO. 12:311-320 
4. Paris Hamelin, A . F Catalon et A. Vaisman. 19 70. S£ro-diagnostic de la 
syphilis utihsant une reaction d'hemagglutination passive avec un anligene 
trcponemique Premiers resultats obtenus. Bulletin de la Societe Francaise de 
Dermatologie et de Svphiligraphie. 77:474-482 
5. Logan. L.C., and Cox. P.M. 1970. Evaluation of a Quantitative Automated 
Microhemagglutination Assay for Antibodies to Trepenema pallidum. AM. 
J CLIN. PATHOL. 53:163 66 
6. Cox. P M.. Logan. L.C., and Stout, G. 1971. Further Studies of a Quantitative 
Automated Microhemagglutination Assay for Antibodies to Treponema 
Pallidum. PUBL HEALTH LAB. 29:43-50 
7. U S. Dept. Health. Education. Welfare. 1971. Microhemagglutination Assav 
for Treponema pallidum Antibodies. (MHA-TP) (Provisional Technique). 
March 2, 1971. 
8 McKav, E.J., ANZIM1LT, 1972. The Micro TPHA; A Comparison with other 
Serological Tests for Syphilis. N'.Z.J. med. Technol. 26: 102-105 
o I uner, A Spcndlingwimmer, I. 1972. An Appraisal of The Treponema 
Pallidum Hemagglutination (TPHA) Test. WHO Document WHO/VDT/RtS/ 
72.2 84 
10. Johnston, N.A. 1972. Treponema pallidum hemagglutination test for Syphilis. 
Evaluation of a Modified Micro-Method. BRIT. J. VEN. DISEASES 
48:472-478 
11 Dasgupta. A. 1972.Usefulness of Treponema pallidum hemagglutination and 
enzymes marker peroxidase tests for the serodiagnosis of syphilis. Indian J . 
Med. Res. 60:987 
12. Coffey. E M . L.L Bradford. L.S. N'aritomi and R.M. Wood. 1972. Evaluation 
of the Qualitative and Automated Quantitative Micro hemagglutination Assay 
for Antibodies to Treponema Pallidum. APPLIED MICROBIOL. 24:26-30. 
13 O’neill, P.. W. Warner. C.S. Nicol. 1973. Treponema pallidum hemaggluti¬ 
nation assay in the routine serodiagnosis of treponemal diseases. Brit. J. 
Vener. Dis. 49:427-431 
14 Garner, M.F . J L Backhouse. G. Daskalopoulos and J.L. Walsh. 1973. 
The Treponema Pallidum Hemagglutination Test (TPHA) in Biological False 
Positives and Leprosy Sera. J. Clin. Path. 26:258-261. 
15. A Fischman. A.D. Bree, and R.A. Lynch. 1974. TPHA and RPL tests for 
yaws antibodies. Brit. J. Vener. Dis. 50:347-349. 
16. Lesinski. J.. B. Dudzisz, E. Kadziewicz. J. Drach, M. Szymczak. 1974. In¬ 
vestigations or. the Specificity of the TPHA test and its value as a screening 
and verification test in Syphilis Diagnosis. WHO Document WHO/VDT/RES/ 
74.317. 
17. Von A. Kern. H. Barthelmes. 1974. Tieponema-pallidum Hamagglutinations- 
(TPHA)-Test. Dermatologische Monatsschrift. 16Q( 1974):257-267. 
18. Dowdcn, S.J., and Stephen J. Millian, 1975. Comparison of the Micro- 
hemagglutination Assay for Antibodies to Treponema pallidum and the 
Automated Fluorescent Treponemal Antibody-Absorption Test. Health 
Laboratory Science 12(1) 20-27, 1975. 
19. Muller. F.. 1976. Moderne immunologische Syphilis-Diagnostik. Sonderdruck 
aus Hamburger Arzteblatt Nr. 3, Mar. 1976. 
Marutacnrad by 
v FU JIREQIQ ITVC 
6-7. Sfwnooctw 4-cfone Tokyo. WJ> Japan 
Revised Oct. 1985 

Appendix 6 
82 
HUMAN T LYMPHOTROPIC VIRUS TYPE I 
(HTLV-I) 
Retro-Tek'HTLV-l ELISA 
An Enzyme Linked Immunosorbent Assay for the Detection of 
Antibody to Human T-Cell Lymphotropic Virus Type 1 (HTLV-I) 
FOR RESEARCH USE ONLY 
Manufactured by 
CELLULAR PRODUCTS. INC 
Buffalo. New York 14202 
Form #043 
May 19. 1988 
Retro-Tek* HTLV-I ELISA 
An Enzyme Linked Immunosorbent Assay for the Detection of 
Antibody to Human T Lymphotropic Virus Type I (HTLV I) 
NAME AND INTENDED USE 
Retro Tek’* HTLV I ELISA is an in vitro qualitative enzyme linked 
immunosorbent assay for the detection of antibodies to HTLV I in 
research specimens The test may be employed to detect antibodies 
in human serum or plasma specimens 
IT IS RECOMMENDEO THAT THE PRODUCT INSERT BE READ IN ITS 
ENTIRETY BEFORE PROCEEDING WITH THE TEST PROCEDURE 
STORAGE 
Assembled test kits and all components within the test kit must be 
stored at 2 8°C 
SUMMARY AND EXPLANATION OF THE TEST 
The ELISA format has been utilized to detect antibodies to viruses 
and the Retro Tek'“ HTLV I ELISA can provide highly specific and 
sensitive results when performed as recommended in this Product 
Insert Each test kit is supplied with HTLV-I Microplates, 
Positive and Negative Controls, and all reagents required to 
detect the presence of antibodies to HTLV-I m human serum or plasma 
The HTLV l is propagated in a permissive cell line and 
supernatants obtained from the cell cultures are purified to yield 
active viral particles After disruption by chemical means, a 
lysate of the HTLV-I is used to coat the wells of 96-well 
microplates Potential protein binding sites within the 
microplates are “blocked" with non-specific proteins and the 
plates are dried and supplied to users along with all necessary reagents 
and controls 
Serum or plasma samples are pre diluted and added to the HTLV-I 
Microplate wells Antibodies specific for HTLV-I proteins, which 
may be present in the sample, bind to the viral proteins which are 
bound to the micrdplate wells A subsequent washing step will 
remove any non-HTLV-l specific antibodies and a goat anti-human 
igG antibody (heavy and light chain specific) conjugated to 
alkaline phosphatase is added to the same wells If human 
antibodies have been bound to the viral proteins coating the 
wells, the alkaline phosphatase conjugate will bind to the 
antigen/antibody complea An enzyme substrate 
(p nitrophenylphosphate) is added and the colorless compound will 
be converted to a detectable yellow substance m proportion to the 
amount of human antibody to HTLV-I which is bound to the well 
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MATERIALS SUPPLIED 
1 HTLV-I Microplale 96-well (12*8 well) microplate coated with 
HTLV-I viral proteins Storage 2 8“C (desiccated) 
2 Positive Control Heat-inactivated human source material 
containing antibody to HTLV-I proteins and negative (or 
Hepatitis B surface antigen Preservative 0 00S% Thimerosal 
and 0 IS sodium azide Storage 2-8°C 
3 Negative Control Human source material negative (or antibody to 
HTLV-I proteins and Hepatitis B surface antigen Preservative 
0 OOSS Thimerosal and 0 1 % sodium azide Storage 2 8°C 
4 Sample/Conjugate Diluent Used to dilute test specimens. 
Positive and Negative Controls, and Conjugate (Contains PBS 
with 20S heat inactivated goat serum, 0 05S Tween-20, and 1 0% 
0SA) Preservative 0 OOSS Thimerosal and 0 1% sodium azide 
Storage 2 8°C 
5 Conjugate Goat Anti-Human iqG (heavy and light chain specific) 
conjugated with alkaline phosphatase, supplied m a lyophilized 
form Storage 2 8°C 
6 Substrate Tablets p Nitrophenylphosphate (pNPP) substrate 
tablets Storage 2 8°C 
7 Substrate Diluent Buffer used to solubilize Substrate Tablets for 
use in ELISA (Contains 1 0M diethanolamine (DEA) with 0 5 mM 
MgClz) Preservative 0 1% sodium azide Storage 2 8X 
8 10X Plate Washing Buffer After dilution, this buffer is 
utilized to wash the HTLV-I Microplate where noted in the Test 
Procedure Section (Contains 10X PBS with 0 5% Tween 20) 
Preservative 1 0“-4 chloroacetamide Storage 2 8"C 
9 Stop Solution 3N NaOH used to stop alkaline phosphatase 
reaction (NaOH is a known caustic reagent, use care in handling) 
Storage 2 8°C 
MATERIALS REQUIRED BUT NOT SUPPLIED 
Micropipettes To deliver 15 ul, 45 ul, 300 ul, and 900 ul 
Multiple (8 or 12) Channel to deliver SO ul and 200 ul 
Multichannel pipette reagent reservoir, 30 ml capacity 
Assorted beakers or flasks to dilute concentrates supplied 
Test tubes (12 x 75 mm) for pre-dilution of sample 
Timer 
Disposable gloves 
Non metallic forceps 
Deionized or distilled water 
37“C dry air incubator 
ELISA plate washer (optional) 
ELISA plate reader (405 nm) or spectrophotometer 
Vacuum pump system (for optional ELISA plate washer) 
Multiple (8 or 12) channel vacuum device for manual wash 
Automatic sample dilutor (optional) 
Autoclave 
Refrigerator 2-8°C 
10 Microplaie Covers 
11 Plate Storage Bag 
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Reuo-Tek'“ 
HTIV-I ELISA TEST KIT FOR DETECTION OF HTLV-I ANTIBODY 
Catalog Number 0801022 Retro Tek,»HTLV 1 ELISA Test 
Kit 576 Determinations 
Catalog Number 0801021 Retro Tek'*HTLV 1 ELISA Test 
Kit 192 Determinations 
0801022 0801021 Component Description 
6 plates 2 plates HTLV 1 Microplate 
96 wells in 12x8 well strips 
1 0ml 0 5ml Positive Control 
1 0ml 0 5ml Negative Control 
0 1ml 0 1ml Conjugate (lyophilized powder) 
2xISSml 125ml Sample/Coniugate Diluent 
ISOml 60ml Substrate Diluent 
SOOml 2x100ml 10X Plate Wash Buffer 
50ml 15ml Stop Solution (Contains NaOH, a 
known caustic reagent) 
31 Tablets 11 Tablets Substrate Tablets 
Storage Bag Storage 
Bag 
Storage Bag for storing unused 
Microplate strips 
18 Plate 
Covers 
6 Plate 
Covers 
Disposable Microplate Covers 
3 All potentially biohazardous materials in this assay kit 
and samples must be disposed of in a manner that will insure 
inactivation of infectious virus Solid wastes 
and vials, HTLV-I Microplates, Positive and Negative Controls 
must be autoclaved for 60 minutes at 121°C Liauid wastes may 
be inactivated by the addition of sodium hypochlorite 
(household bleach) to achieve a final concentration of 1 0% 
sodium hypochlorite for a period of at least thirty minutes 
The inactivated material may then be discarded down the sink 
dram followed by copious amounts of water 
4 The components of this kit have been assembled and tested as a 
unit Do not interchange components from this kit with others 
manufactured by Cellular Products or other manufacturers 
5 An expiration date is clearly stamped on outer kit labeling Do not 
use the kit or components beyond the labeled expiration date 
6 Do not handle Substrate Tablets (pNPP) with bare fingers or 
permit contact with exposed skin Use non metallic forceps to 
transfer the tablets The tablets and diluted pNPP reagent must be 
protected from direct light 
7 DO NOT MOUTH PIPETTE under any circumstances Use of 
pipetting aids is required 
8 Stop Solution is 3N NaOH, a known caustic substance and 
irritant to mucous membranes Wear gloves and eye protection 
when working with this reagent 
9 Avoid microbial contamination of kit reagents Use aseptic 
technique when withdrawing component aliquots from primary 
containers 
10 Color developement is inhibited by residual amounts of diluted 
Plate Wash Buffer left in test wells prior to the addition and 
incubation of Substrate Plates must be blotted thoroughly 
prior to the addition of Substrate 
WARNINGS ANO PRECAUTIONS FOR USERS 
1 TheRetro-Tek'” HTLV-I Microplates must be treated as if capable of 
transmitting htiv i Disposable gloves must be worn at all times 
Used or outdated microplates plates must be discarded by 
autoclaving The HTLV-I Microplate has been coated with HTLV I 
proteins which have been inactivated by detergent lysis 
2 Both the Positive and Negative Controls have been found to be 
negative for Hepatitis B surface antigen The Positive Control has 
been heated at S6°C for sixty minutes to inactivate any HTLV I 
which might be present However, care should be taken to handle 
each of the controls as potential biohazards 
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REAGENT PREPARATION 
1 The Sample/Conjugate Diluent is used directly as supplied No 
dilution is requireo 
2 The Positive and Negative Controls are prepared 
exactly as described for the test sera Pre dilute 
controls by adding 45 ul of the control to 900 ul of 
Sample/Con|ugate Diluent and then introducing 200 ul of 
diluted sample to each of the appropriate wells The diluted 
Positive Control is analyzed in quadruplicate and the diluted 
Negative Control is analyzed m duplicate 
3 The lyophilized Conjugate must be reconstituted by the 
addition of 1 0 ml of Sample/Conjugate Diluent to 
provide a Stock Solution of Conjugate which is diluted as 
described below to provide a working solution of Conjugate 
as needed Reconstitution of the lyophilized Comuqate with 
Sample/Conjugate Diluent should be performed at least 18 to~T4 
hours prior to use in preparing the working solution 
The resolubifized Stock Solution is stable for at least 3 
months when stored at 2-8“C Any working solution of 
Conjugate should be discarded at the end of the day 
4 The Substrate Tablets are dissolved in Substrate 
Diluent according to the following schedule 
CAUTION PREPARE SUBSTRATE SOLUTION NO SOONER THAN 30 
•ETINUTES PRIOR TO USE ANY SUBSTRATE SOLUTION 
WTHJSED WITHIN-30 MIN0TES UE PREPARATION MUST 
ernrecaRDED"- 
Number of Test 
Wells* 
Number of Substrate 
Tablets 
Volume of 
Diluent 
0 20 1 0 5 0 ml 
21 40 2 0 10 0 ml 
41 60 3 0 15 0 ml 
61 80 4 0 20 0 ml 
81 96 5 0 25 0 ml 
‘Including all control samples 
5 The 10X Plate Wash buffer Concentrate must be diluted ten fold 
prior to use with distilled or deionized water The following 
dilution schedule supplies sufficient diluted Plate Wash 
Buffer for use in manual washing procedures 
No of Vol of Stock Sol Vol of S/C Final Volume of 
Tests* of Conjugate Diluent Working Solution Number of Test Vol. of 10X Volume of Final 
Wells* Concentrate Water Volume 
0 20 10 ul 5 0 ml 5 01 ml 
21 40 20 ul 10 0 ml 10 02 ml 0 24 6 5 ml 58 5 ml 65 0 ml 
41 60 30 ul 15 0 ml 15 03 ml 25 48 13 0 ml 1 17 0 ml 130 0 ml 
61 SO 40 ul 20 0 ml 20 04 ml 49 72 20 0 ml 180 0 ml 200 0 ml 
81 96 50 ul 25 0 ml 25 05 ml 73 96 25 0ml 225 0ml 250 0 ml 
c i'lji* UaJ V* l> .s-C 3 ; ' 
* Including all control samples ‘Including all control samples 
For the sake of accuracy, it is recommended that the 
preparation of a Working Solution of Conjugate utilize the 
above schedule so that quantities less than 10 ul of Stock 
Conjugate Solution are not pipetted 
If automated plate washers are employed, prepare the 
appropriate amount of diluted Plate Wash Buffer as required 
to fill and prime all feed lines 
Diluted Plate Wash Puffer can be held at room temperature and 
used up to 3 weeks after preparation- 
6 Stop Solution is used directly as supplied No dilution is required 
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SPECIMEN PREPARATION 
CAUTION: All research specimens analyzed in this assay should be 
handled as though capable of transmitting infectious 
agents 
For optimal performance of the Retro Tek'“ HTIV-I ELISA, serum or 
plasma samples should be tested within 24 hours of collection If 
samples are not analyzed immediately, store at 2 8°C until ready 
to test If testing is delayed longer than 24 hours, storespecimens at 
20°C or colder 
Avoid multiple freeze thaw cycles 
TEST PROCEDURE 
3 Using a micropipettor adjusted to 200 ul, place 200 ul of the 
pre diluted Positive Control into each of four separate wells 
of the HTLV-I Microplate (If an automated dilutor is employed, 
steps two (2) and three (3) are performed simultaneously) 
4 Using a micropipettor adjusted to 200 ul, place 200 ul of the 
pre diluted Negative Control into each of two separate wells 
of the HTLV-I Microplate (If an automated dilutor is employed, 
steps two (2) and four (4) are performed simultaneously) 
5 Using a micropipettor adjusted to 200 ul, place 200 ul of the 
pre diluted serum or plasma into a single well ofthe HTLV-I 
Microplate Each sample evaluated in the Retro-Tek"* HTLV-I ELISA 
test must be placed into a separate well of the HTLV-I Microplate A 
separate pipette tip should be used for each individual specimen 
(if an automated dilutor is employed, steps two (2) and five (5) 
are performed simultaneously) 
CAUTION: ALL RESEARCH SPECIMENS TO BE ANALYZED MUST BE 
HANOLED AS IF CAPABLE OF TRANSMITTING INFECTIOUS 
AGENTS FURTHERMORE, ALL POSITIVE SERUM 
CONTROLS AND HTLV-I MICROPLATES CONTAINED IN THE 
RetfO-Tek~ HTLV-I ELISA TEST KIT MUST ALSO BE 
HANDLED AS IF CAPABLE OF TRANSMITTING INFECTIOUS 
1 Allow all test components to warm to room temperature before 
starting test procedure If the entire 96-well microplate is not used 
remove only the strips of wells that will be used and reseal the 
remaining unused wells in the Plate Storage Bag along with the 
desiccant Label the Plate Storage Bag with lot number and 
expiration date of the kit and store the resealed microplate at 
2 8 C The remaining test wells may be used until the expiration 
date 
2 Pre-dilute all test and control specimens 1/2 1 usina the followmn 
protocol -- 
THE FOLLOWING DILUTIONS PROVIDE SUFFICIENT VOLUME TO PERMIT 
FOUR (4) WELLS OF THE POSITIVE CONTROL, TWO (2) WELLS OF THE 
NEGATIVE CONTROL AND ONE (1) WELL OF THE TEST SPECIMEN TO BE 
ANALYZED 
Positive Control Add 45 ul of Positive Control to 900 ul of 
Sample/Conjugate Diluent in a test tube 
Negative Control Add 45 ul of Negative Control to 900 ul of 
Sample/Conjugate Diluent in a test tube 
Test Specimens Add 15 ul of Test Specimen to 300 ul 
of Sample/Conjugate Diluent in a test tube 
Alternatively, an automated dilutor may be used to achieve the 
delivery of 200 ul of a 1/21 dilution of sample in Sample/Coniugate 
Diluent to the test well 
IN ORDER TO PROVIDE A REAGENT BLANK WELL, BE CERTAIN TO 
placE^OO ul Or SAMPLE/CONJUGATE DllUENTTO ONE WELL TWe 
ABSOfraAwrcwuror the reagent blan^wll mu^t &e 
SUBTRACTED FROM THE ABSORBANCE VALUE OF EACH WELL USED TO 
ANALYZE THE POSITIVE AND NEGATIVE CONTROLS AND THE 
UNKNOWN TEST SPECIMENS ALTERNATIVELY, ELISA PLATE READERS 
SO EQUIPPED SHOULD BE PROGRAMED TOAUTOMATICALLY 
SUBTRACT THE ABSORBANCE VALUE OF THE REAGENT BLANK WELL 
FROM ALL OTHER WELLS 
6 Cover the Microplate with a plate cover to prevent evaporation and 
incubate for 60 minutes (+/5 minutes) at 37°C + /-1°C DO NOT 
STACK PLATES IN THE INCUBATOR IF MORE THAN ONE PLATE IS 
ANALYZED 
7 Aspirate the entire contents of each well with a vacuum device 
8 Wash each well of the Microplate being analyzed six times by 
adding a quantity of diluted 10X Plate Wash Buffer to each well and 
then aspirating When using multichannel pipettes for the wash 
step, add 200 ul diluted wash buHer per well When using 
automated or semi automated plate wash equipment, use 300 ul 
diluted plate wash buffer per well 
9 Thoroughly blot microplate by sharply striking the inverted 
microplate on a pad of absorbent towels placed on the benchtop 
Continue striking until no droplets remain in the wells 
10 Add 200 ul of Working Solution of Conjugate to each well of the 
microplate being analyzed 
11 Cover the microplate with a plate cover and incubate for 60 
minutes ( + /- 5 minutes) at 37°C + /- 1°C DO NOT STACK 
PLATES IN THE INCUBATOR IF MORE THAN ONE PLATE IS 
ANALYZED 
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12 Aspirate the entire contents of each well with a vacuum 
device 
13 Wash each well of the microplate being analyzed si* times 
e*actly as described above in Step 8 and 9 
CAUTION RESIDUAL PLATE WASH BUFFER IN TEST WELLS WILL 
INHIBIT COLOR DEVELOPMENT EXAMINE WELLS AND 
REBLOT, IF NECESSARY. TO REMOVE ANY RESIDUAL 
BUFFER 
14 Add 200 ul of previously reconstituted Substrate (i e . 
Tablets in Substrate Diluent) to each well of the microplate 
being analyzed The Substrate Solution should be formulated 
within 30 minutes prior to its use Any unused Substrate 
Solution should be discarded 
15 Cover the microplate with a plate cover and incubate it 
for 30 minutes ( ♦ /■ 5 minutes) at 37°C + /- 1°C DO NOT STACK 
PLATES IN THE INCUBATOR IF MORE THAN ONE PLATE IS 
ANALYZED 
16 Stop the ELISA reaction by adding 50 ul of Stop Solution 
to each well of the microplate being analyzed 
CALCULATION OF RESULTS 
(A) Determination of the mean of Negative Serum Control 
After adiustmg for the blank, add the two separate ELISA readings 
of the Negative Serum Control together and divide the result by 
(! e calculate the average absorbance of the two separate 
Negative Serum Control welfe) The mean of the Negative Serum 
Control ELISA readings must be in the range of 0 000 O 0 to 
0 200 O D 
(B) Determination of the mean of the Positive Serum Control 
1 At least three of the four absorbance readings of the 
Positive Serum Control must be in the range of 0 800 O D 
to 2 100 O D after subtracting of the blank well, AND 
2 At least three of the four absorbance readings meeting 
the above requirement must be within 30% of the mean 
absorbance reading of all wells meeting the above 
3 Calculate the mean of the absorbance readings meeting 
both criteria listed above 
17 Read the absorbance of each well within 60 minutes of 
stopping the reaction of the microplate being analyzed 
by placing the plate into an ELISA plate reader equipped 
with a 405 nm filter A single wavelength (i e 405 nm) 
or dual wavelength (i e using a 405 nm primary filter) may 
be used to read tne HTLV-l Microplate ELISA microplate 
readers so equipped should be programed to read all 
absorbance readings against the blank well. Alternatively, 
read all wells against air and subtract the absorbance of tne 
blank well from all other control and specimen-containing 
wells. 
EXAMPLE 
Absorbance values of four Positive Serum Controls 
Sample 1 1 400 
Sample 2 1 502 
Sample 3 0 803 
Sample 4 1 376 
All Absorbance values meet criteria (1) above 
a Determination of mean 1 270 
b 30% of mean 0 381 . . 
Only Sample 1, Sample 2. and Sample 4 meet critena 
(2) above therefore, the mean of Sample 1. Sample 2, 
and Sample 4,s 1 426 This value represents the 
Positive Serum Control 
(C) Determination of Cutoff Value 
In order to determine the cutoff value, divide the mean of the 
Positive Control as determined m (B) iy_4_ \hl4pv?eadinas 
cutoff value between non reactive andreactive readings 
INTERPRETATION OF RESULTS: 
Specimens which yield absorbance values lesstha" °''XlVo°HTLV ! 
CutoH Value should be considered negative or 
while specimens which yield absorbance va ue g , , hTLV I 
Cutoff Value should be considered positive for antibodies to HTLV 
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Appendix 7 
QUESTIONNAIRE 
(Note: A few questions or parts thereof were deleted in the 
final analysis after they were felt to be non-contributory or 
ambiguous). 
Please answer these questions as honestly as you can. If 
there is any question you don't understand feel free to ask me to 
explain. 
1. Name: (on separate sheet) I.D: 
2. Has anyone in your family, living or dead, ever had a nerve 
disease? l.Yes 2.No Who?_ 
3. Has anyone in your family, living or dead, ever had 
unexplained problems in walking? l.Yes 2.No Who?_ 
4. What were the first signs of your disease?_ 
When did they occur?_ 
5. Where were you living when you first noticed signs of the 
disease? l.St. Andrew 2.Christ Church 3.St. George 
4.St. James 5.St. John 6.St. Joseph 7.St. Lucy 
8.St. Michael 9.St. Peter 10.St. Philip 11.St. Thomas 
20.Other West Indian island 30.England 40.Other 
6. How long were you living in above when you first noticed 
signs of the disease?_years. 
7. When you first noticed signs, were you: 
1.Married 2.Divorced 3.Separated 4.Widowed 5.Never married 
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8. Spastic gait: 1.Present 2.Absent 
9. Degree of disability: 1.Walks unaided 2.Walks with support 
3.Unable to stand or walk or does so rarely. 
10. Do you ever have bladder problems? 1.Never 2.Rarely 
3.Sometimes 4.Fairly often 5.Very often 
What problems? 1.Frequency 2.Retention 3.Both 
When did you first notice them? Month and year_ 
11. Do you ever have leg cramps? 1.Never 2.Rarely 3.Sometimes 
4.Fairly often 5.Very often 
When did you first notice?_ 
12. Do you ever get back pains? 1.Never 2.Rarely 3.Sometimes 
4.Fairly often 5.Very often 
When did you first notice?_ 
13. Do your legs ever feel weak? 1.Never 2.Rarely 3.Sometimes 
4.Fairly often 5.Very often 
When did you first notice?_ 
14. Do your feet ever tingle or burn? 1.Never 2.Rarely 
3.Sometimes 4.Fairly often 5.Very often 
When did you first notice?_ 
15. Do you ever have difficulty with bowel movements 
(constipation)? 1.Never 2.Rarely 3.Sometimes 
4.Fairly often 5.Very often 
When did you first notice?_ 
16. Did you ever have blurred vision or lose your sight in one or 
both eyes? l.Yes 2.No 
Did you ever have double vision? l.Yes 2.No 
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17. Has anyone in your family, living or dead, ever had leukemia 
(blood cancer) l.Yes_ 2.No 
18. How many pregnancies have you had?_ 
19. How many abortions have you had?_ 
20. Were you using any prescribed drugs or medications in the 6 
months before the first signs? l.Yes 2.No 
21. What health problems do you have?_ 
22. How many blood transfusions, if any, did you have before you 
noticed the first signs?_ When?_ 
23. How many injections did you receive in the year before you 
noticed the first signs? 1. 0 2. 1 or few 3. Several 
Who gave them to you?_ When?_ 
24. Were you breast-fed as a baby? l.Yes 2.No 3.Don't know 
25. Did you ever have....? When? (If not sure say don't know) 
Lyme disease_ Conjunctivitis_ 
Unexplained skin rashes_ Diphtheria_ 
Syphilis_ Yaws_ Urinary infection?_ 
Gonorrhea_ Head injuries_ Other_ 
26. How many cigarettes did you smoke per day? 1. 0 2. 1-2 
3. 3-5 4. 6-10 5. More than ten. 
27. How many alcoholic drinks did you drink per week? 1. 0 
2. 1-2 or less 3. 3-5 4. 6-10 5. More than 10. 
28. Did you eat seafood? How often? (1.Never etc.) Conch_ 
Clams_ Crabs_ Shrimp_ Other shellfish _ 
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29. How often per week did you eat fish__ 
peas_ mushrooms_ 
cassava_ (type and frequency) 1. 0 2.Once 
every few weeks or less 3. 1-2 4. 3-5 5. 6 or more 
Did you prepare your own cassava? l.Yes 2.No 
30. Did you use folk medicine? How often? (1.Never etc.)_ 
How did you take it? l.By mouth 2.Ointment 3.Injection 
4.Other_ 
31. What unprescribed drugs did you use?_ 
32. Did you use bush teas? How often? (1.Never etc.)_ 
33. Did you raise any farm animals? l.Yes, within the last 10 
years 2.Yes, more than 10 years ago 3.No 
34. Did you keep any pets? l.Yes, within the last 10 years 
2.Yes, more than 10 years ago 3.No 
35. Did you work with...? How often? (1.Never etc.) 
Insecticides_ Pesticides_ 
Disinfectants_ Other chemicals or poisonous 
materials_ 
36. Gender: 1. M 2. F 
37. Date of birth: Month_Day_Year_ 
38. Race: 1.Black 2.White 3.Mixed 4.Indian 5.Other_ 
39. Where were you born? (Options as in question 5.) 
40. Where do you live now? (Options as in question 5.) 
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41. Are you currently : 1.Married 2.Divorced 3.Separated 
4.Widowed 5.Never married 
Before you noticed the first signs: 
42. What was your job?_ 
1.Service 2.Trade 3.Professional 4.Unemployed 
43. What was your highest level of education? l.No formal 
education 2.Primary school 3.Secondary or high school 
4.University 5.Post-graduate education 
44. How many persons lived in your home besides you? Include all 
children_ 
45. What were their relationships to you and what were their 
ages?_ 
46. Is your sex drive decreased? l.No, it is as usual 
2.Yes, a little 3.Yes, very much 
When did you first notice?_ 
47. How often did you have sex before you noticed the 
first signs? 1.Never 2.Once every few years 3.Once every 
few months 4.Once every few weeks 5. 1-2 times per week 
6. 3-5 times per week 7. More than 5 times per week 
48. How many different sexual partners did you have in the 6 
months before you noticed the first signs? 
1. None 2. One 3. Two 4. Three 5. Four to eight 
6.More than eight 
49. Before you noticed the first signs did you and your partners 
use... How often? (1.Never etc.) Condom_ Diaphragm_ 
Pill_ Other type of contraception_ 
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50. Do you have any problems in getting erections? 1.Never 
2.Rarely 3.Sometimes 4.Fairly often 5.Very often 
51. Have you ever taken by needle...How often? (1.Never etc.) 
Heroin_ Cocaine_ Other drugs_ 
52. Have you ever had sex with someone who has taken by 
needle... How often? (1.Never etc.) Heroin_ Cocaine_ 
Other rugs_ 
53. Have you ever had sex with a member of the same sex? How 
often? 1.Never 2.Rarely 3.Sometimes 4.Fairly often 
5.Very often 
54. Have you ever travelled abroad? 1.Never 2.Slight (1 or 2 
times) 3.Moderate (3-5 times) 4.Extensive (more than 5 
times) Where?_ 
55. What are the names and ages of your brothers and sisters, 
your parents, and your children? _ 
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Appendix 8 
ISOLATION OF LYMPHOCYTES 
. Collect blood in a sterile heparinized vacutainer 
(The following 2 steps are done in a flow hood) 
. Pipette at least 2.5 ml of Ficoll into 2 sterile 30-40 
ml tubes 
. Add delicately ~5 ml of blood on top of the Ficoll 
. Centrifuge 30 minutes at 3000 rpm 
. Remove top plasma layer which may be discarded or 
frozen for eventual antibody detection 
. Collect leukocytes in buffy coat using sterile 
Pasteur pipettes 
. Place in sterile container and add 10 ml of RPMI-1640 
medium 
. Centrifuge at 2000 rpm for 10 minutes 
. Discard supernatant 
. Resuspend the cell pellet in 5 ml of RPMI-1640 medium 
containing 10% fetal calf serum, 2-mercaptoethanol 
(10 5 M), antibiotics, phytohemagglutinin (10 ug/ml), 
anti yinterferon serum and polybrene (2 ug/ml); tap 
tube to mix 
. Incubate for 3 days at 37°C 
. After stimulation, centrifuge cells, discard 
supernatant and resuspend in 5 ml of complete 
medium without phytohemagglutinin; tap tube to mix 
. Add 5 ml growth medium twice a week until container is 
half-full, then pipette off medium and start over 
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